Oxadiazoles as agonists of muscarinic M1 and / or M4 receptors
By designing highly selective heterocyclic compounds as muscarinic M1 and M4 receptor agonists, the problems of insufficient selectivity and significant side effects of existing drugs in the treatment of Alzheimer's disease, schizophrenia, and pain have been solved, achieving safer and more effective treatment results.
Patent Information
- Application Number
- CN202410873092.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-22
- Filing Date
- 2019-06-24
- Publication Date
- 2024-11-29
AI Technical Summary
Existing muscarinic M1 and M4 receptor agonists have problems with insufficient selectivity and significant side effects in the treatment of Alzheimer's disease, schizophrenia, and pain.
A series of compounds were developed that are highly selective agonists for M1 and/or M4 receptors, with reduced agonistic effects on M2 and M3 receptors. High affinity and selective agonism of M1 and M4 receptors were achieved through the design of heterocyclic compounds with specific structures.
It improves the selectivity and effectiveness of treatments for Alzheimer's disease, schizophrenia, and pain, reduces side effects, and provides safer treatment options.
Smart Images

Figure CN119039284A_ABST
Abstract
Description
[0001] This application is a divisional application of an application filed on June 24, 2019, with application number 201980054880.1, and invention name “Oxadiazoles as agonists of muscarinic M1 and / or M4 receptors”. Technical Field
[0002] The present invention relates to a class of heterocyclic compounds, their salts, pharmaceutical compositions containing them and their use in human therapy. In particular, the present invention relates to a class of compounds that are agonists of muscarinic M1 receptors and / or M4 receptors and are therefore useful for treating Alzheimer's disease, schizophrenia, cognitive disorders and other diseases mediated by muscarinic M1 receptors / M4 receptors, as well as treating or alleviating pain. Background of the Invention
[0004] Muscarinic acetylcholine receptor (mAChR) is a member of the G protein-coupled receptor superfamily that mediates the effects of the neurotransmitter acetylcholine in both the central nervous system and the peripheral nervous system. Five mAChR subtypes (M1 to M5) have been cloned. M1 mAChR is mainly expressed postsynaptically in the cortex, hippocampus, striatum and thalamus; M2 mAChR is mainly located in the brainstem and thalamus, but is also located in the cortex, hippocampus and striatum, in which M2 mAChR is present on cholinergic synaptic terminals (Langmead et al., 2008 Br J Pharmacol). However, M2 mAChR is also expressed peripherally on cardiac tissue (M2 mAChR mediates the innervation of the vagus nerve of the heart in cardiac tissue) and is expressed peripherally in smooth muscle and exocrine glands. M3 mAChRs are expressed at relatively low levels in the CNS but are widely expressed in smooth muscle and glandular tissues such as sweat and salivary glands (Langmead et al., 2008 Br J Pharmacol).
[0005] Muscarinic receptors in the central nervous system, particularly M1 mAChR, play a key role in mediating higher cognitive processing. Diseases associated with cognitive impairment, such as Alzheimer's disease, are accompanied by the loss of cholinergic neurons in the basal forebrain (Whitehouse et al., 1982 Science). In schizophrenia, which is also characterized by cognitive impairment, mAChR density is reduced in the prefrontal cortex, hippocampus, and caudate putamen of schizophrenia subjects (Dean et al., 2002 Mol Psychiatry). In addition, in animal models, the blockade or damage of central cholinergic pathways leads to significant cognitive deficits, and non-selective mAChR antagonists have been shown to induce psychotomimetic effects in patients with mental illness. Cholinergic replacement therapy is largely based on the use of acetylcholinesterase inhibitors to prevent the decomposition of endogenous acetylcholine. These compounds have shown efficacy against symptomatic cognitive impairment in the clinic, but produce dose-limiting side effects caused by stimulation of peripheral M2 mAChRs and M3 mAChRs, including gastrointestinal motility disturbances, bradycardia, nausea and vomiting (http: / / www.drugs.com / pro / donepezil.html; http: / / www.drugs.com / pro / rivastigmine.html).
[0006] Additional discovery work is devoted to identifying direct M1mAChR agonists that target an increase in cognitive function. Such work has led to the identification of a series of agonists, exemplified by compounds such as xanomeline, AF267B, sabcomeline, milameline, and cevimeline. Many of these compounds have been shown to be highly effective in preclinical cognitive models of both rodents and / or non-human primates. Milameline has been shown to be effective in rodents in terms of working and spatial memory relative to scopolamine-induced deficits; sabcomeline has demonstrated efficacy in marmosets in visual object discrimination tasks, and xanomeline reverses cognitive performance deficits induced by mAChR antagonists in a passive avoidance paradigm.
[0007] Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting the elderly (26.6 million people worldwide in 2006), leading to severe memory loss and cognitive dysfunction. The etiology of the disease is complex, but is characterized by two hallmark brain sequelae: aggregates of amyloid plaques mainly comprising amyloid-β peptides (Aβ) and neurofibrillary tangles formed by hyperphosphorylated tau proteins. The accumulation of Aβ is considered to be the main feature in the progression of AD, and therefore, many putative therapies for the treatment of AD are currently aimed at inhibiting Aβ production. Aβ is derived from the proteolytic cleavage of membrane-bound amyloid precursor protein (APP). APP is processed by two routes of non-amyloidogenic and amyloidogenic. Cleavage of APP by γ-secretase is common to both pathways, but in the former, APP is cleaved by α-secretase to produce soluble APPα. The cleavage site is within the Aβ sequence, thereby preventing its formation. However, in the amyloidogenic route, APP is cleaved by β-secretase to produce soluble APPβ and also Aβ. In vitro studies have shown that mAChR agonists can promote APP to be processed towards soluble, non-amyloidogenic pathways. In vivo studies have shown that mAChR agonist AF267B changes disease-like pathology in 3xTgAD transgenic mice, a model of different stages (component) of Alzheimer's disease (Caccamo et al., 2006 Neuron). Finally, mAChR agonist Cevimeline has been shown to give a small but significant reduction in Aβ cerebrospinal fluid levels in Alzheimer's patients, thus confirming potential disease-modifying efficacy (Nitsch et al., 2000 Neurol).
[0008] In addition, preclinical studies have shown that mAChR agonists exhibit atypical antipsychotic profiles in a series of preclinical paradigms. The mAChR agonist xanomeline reverses the behavior driven by multiple dopamines, including the movement induced by amphetamines in rats, the climbing induced by apomorphine in mice, the flipping driven by dopamine agonists in rats with unilateral 6-OH-DA damage, and the amphetamine-induced movement in monkeys (without EPS susceptibility) is unstable. mAChR agonists have also been shown to inhibit dopamine cell discharge and conditioned avoidance of A10 rather than A9, and induce c-fos expression in the prefrontal cortex and nucleus accumbens of rats rather than in the striatum. These data all show atypical antipsychotic profiles (Mirza et al., 1999 CNSDrug Rev). Muscarinic receptors have also been involved in the neurobiology of addiction. The reinforcing effects of cocaine and other addictive substances are mediated by the mesolimbic dopamine system, where behavioral and neurochemical studies have shown that cholinergic muscarinic receptor subtypes play an important role in the regulation of dopaminergic neurotransmission. For example, M(4)(- / -) mice exhibit significantly enhanced reward-driven behaviors due to exposure to cocaine (Schmidt et al. Psychopharmacology (2011) Aug; 216(3): 367-78). In addition, xanomeline has been shown to block the effects of cocaine in these models.
[0009] Muscarinic receptors are also involved in the control of movement and may represent a therapeutic target for movement disorders such as Parkinson's disease, ADHD, Huntington's disease, Tourette syndrome, and other syndromes associated with dopaminergic dysfunction as an underlying pathogenic factor driving the disease.
[0010] Xanomeline, sabcomeline, miramemline and cevimeline have all progressed to different stages of clinical development for the treatment of Alzheimer's disease and / or schizophrenia. Phase II clinical studies using xanomeline have confirmed the effectiveness of xanomeline relative to a variety of cognitive symptom domains, including behavioral disturbances and hallucinations associated with Alzheimer's disease (Bodick et al., 1997 Arch Neurol). This compound has also been evaluated in a small Phase II study of schizophrenia patients, and when compared with placebo controls, a significant reduction in positive and negative symptoms is given (Shekhar et al., 2008 Am J Psych). However, in all clinical studies, xanomeline and other related mAChR agonists have shown unacceptable safety limits regarding cholinergic side effects, including nausea, gastrointestinal pain, diarrhea, sweating (excessive sweating), hypersalivation (excessive saliva secretion), syncope and bradycardia.
[0011] Muscarinic receptors are involved in central pain and peripheral pain. Pain can be divided into three different types: acute, inflammatory and neuropathic. Acute pain plays an important protective function in keeping the organism safe from stimulation that may cause tissue damage, but requires the management of postoperative pain. Inflammatory pain can occur for many reasons including tissue damage, autoimmune response and pathogen invasion, and is triggered by the effects of inflammatory mediators such as neuropeptides and prostaglandins that cause neuronal inflammation and pain. Neuropathic pain is associated with abnormal pain sensation to non-painful stimuli. Neuropathic pain is associated with many different diseases / traumas, such as spinal cord injury, multiple sclerosis, diabetes (diabetic neuropathy), viral infections (such as HIV or herpes). Due to the side effects of disease or chemotherapy, neuropathic pain is also common in cancer. The activation of muscarinic receptors has been shown to be analgesic in many pain states by activating receptors in the higher pain centers in the spinal cord and the brain. Increasing endogenous acetylcholine levels by acetylcholinesterase inhibitors, directly activating muscarinic receptors with agonists or allosteric modulators have been shown to have analgesic activity. In contrast, blocking muscarinic receptors with antagonists or using knockout mice increases pain sensitivity. Evidence for a role of the M1 receptor in pain is reviewed by DF Fiorino and M. Garcia-Guzman, 2012.
[0012] Recently, a small number of compounds have been identified that exhibit improved selectivity for the M1 mAChR subtype relative to peripherally expressed mAChR subtypes (Bridges et al., 2008 Bioorg Med Chem Lett; Johnson et al., 2010 Bioorg Med Chem Lett; Budzik et al., 2010 ACS Med Chem Lett). Despite the increased level of selectivity relative to the M3 mAChR subtype, some of these compounds retain significant agonist activity at both this subtype and the M2 mAChR subtype. Herein, we describe a series of compounds that unexpectedly exhibit high levels of selectivity for the M1 and / or M4 mAChRs relative to the M2 and M3 receptor subtypes. Summary of the invention
[0013] The present invention provides compounds having activity as muscarinic M1 and / or M4 receptor agonists. More particularly, the present invention provides compounds that exhibit selectivity for the M1 and / or M4 receptors relative to the M2 and M3 receptor subtypes.
[0014] Therefore, in a first embodiment (Embodiment 1.1), the present invention provides a compound of formula (1):
[0015]
[0016] or a salt thereof, wherein:
[0017] X 1 and X 2 are saturated hydrocarbon groups which together contain a total of five to nine carbon atoms and zero or one oxygen atom and are linked together such that the moieties:
[0018]
[0019] forming a monocyclic or bicyclic ring system;
[0020] X 3 and X 4 are saturated hydrocarbon groups which together contain a total of three to six carbon atoms and are linked together such that the moieties:
[0021]
[0022] forming a monocyclic or bicyclic ring system;
[0023] R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; or R 1 With R 2 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof;
[0024] R 2 is selected from hydrogen; fluorine; cyano; hydroxyl; amino; and C optionally substituted by one to six fluorine atoms 1-3 A hydrocarbon group, and wherein one of the carbon atoms of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S and their oxidized forms; or R 2 With R 1 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof;
[0025] R 4 H, halogen, OH, CN, C 1-6 Alkyl group or C 3-6Cycloalkyl groups, wherein the alkyl groups and the cycloalkyl groups are optionally substituted by one or more fluorine atoms, and wherein any one atom of the alkyl group or the cycloalkyl group may be optionally replaced by an O heteroatom;
[0026] R 5 is selected from hydrogen; COCH3; non-aromatic C optionally substituted by one or more fluorine atoms 1-10 A hydrocarbon group, wherein C 1-10 Any atom of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S; the group -(CH2) n - aryl, wherein n is 0-3; or R 5 Can be used with R 6 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms;
[0027] R 6 is selected from hydrogen; non-aromatic C optionally substituted by one or more fluorine atoms 1-10 A hydrocarbon group, wherein C 1-10 Any atom of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S; the group -(CH2) n - aryl, wherein n is 0-3; or R 6 Can be used with R 5 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; and
[0028] R 7 is a non-aromatic C optionally substituted by one or more fluorine atoms 1-6 Hydrocarbon group.
[0029] In another embodiment (Embodiment 1.2), the present invention provides a compound of formula (1a):
[0030]
[0031] or a salt thereof, wherein:
[0032] X 1 and X 2 are saturated hydrocarbon groups which together contain a total of five to nine carbon atoms and zero or one oxygen atom and are linked together such that the moieties:
[0033]
[0034] forming a monocyclic or bicyclic ring system;
[0035] X3 and X 4 are saturated hydrocarbon groups which together contain a total of three to five carbon atoms and are linked together such that the moieties:
[0036]
[0037] forming a monocyclic or bicyclic ring system;
[0038] R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; or R 1 With R 2 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof;
[0039] R 2 is selected from hydrogen; fluorine; cyano; hydroxyl; amino; and C optionally substituted by one to six fluorine atoms 1-3 A hydrocarbon group, and wherein one of the carbon atoms of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S and their oxidized forms; or R 2 With R 1 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof;
[0040] R 4 Is H or C 1-3 Alkyl groups;
[0041] R 5 is selected from hydrogen, COCH3, non-aromatic C optionally substituted by one or more fluorine atoms 1-6 A hydrocarbon group, or R 5 Can be used with R 6 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms;
[0042] R 6 is selected from hydrogen, non-aromatic C optionally substituted by one or more fluorine atoms 1-6 A hydrocarbon group, or R 6 Can be used with R 5joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; and
[0043] R 7 is a non-aromatic C optionally substituted by one or more fluorine atoms 1-6 Hydrocarbon group.
[0044] Particular and preferred compounds of formula (1) are as defined in Embodiments 1.3 to 1.42 below:
[0045] 1.3 Compounds according to Embodiments 1.1 or 1.2, wherein R 1 is an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.
[0046] 1.4 A compound according to Embodiment 1.3 wherein the optionally substituted ring is phenyl, pyrazolyl, pyrrolidinyl or pyrrolidinonyl.
[0047] 1.5 A compound according to Embodiment 1.3 or 1.4, wherein the optional substituents of the 5-membered or 6-membered ring are selected from C1-C3 alkyl, C1-C3 alkoxy, CONR 5 R 6 , halogen, cyano, oxo, hydroxy, amino or an optionally substituted heterocycle containing 1 or 2 heteroatoms selected from O or N.
[0048] 1.6 A compound according to Embodiment 1.3 or 1.4 wherein the optional substituent of the 5-membered or 6-membered ring is an optionally substituted pyrazole ring.
[0049] 1.7 A compound according to Embodiment 1.6 wherein the optional substituent of the pyrazole ring is C1-C3 alkyl.
[0050] 1.8 Compounds according to Embodiments 1.1 or 1.2, wherein R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 .
[0051] 1.9 Compounds according to Embodiments 1.1 or 1.2, wherein R 1 Selected from:
[0052]
[0053]
[0054]
[0055] 1.10 A compound according to Embodiment 1.1 or 1.2, wherein R 1 With R 2 Connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
[0056] 1.11 A compound according to Embodiment 1.10 wherein R 1 and R 2 are connected to form an optionally substituted monocyclic ring selected from pyrrolidonyl and oxazolidinonyl.
[0057] 1.12 A compound according to Embodiment 1.10 wherein R 1 and R 2 are connected to form an optionally substituted indolonyl ring.
[0058] 1.13 A compound according to Embodiment 1.10 wherein the monocyclic or bicyclic ring is selected from:
[0059]
[0060]
[0061] 1.14 A compound according to any one of Embodiments 1.10 to 1.13, wherein the optional substituents of the monocyclic or bicyclic ring are selected from C1-C6 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl, amino or a group -(CH2) n -aryl, wherein n is 0-3.
[0062] 1.15 A compound according to any one of Embodiments 1.10 to 1.14 wherein the optional substituent of the monocyclic or bicyclic ring is methyl or ethyl.
[0063] 1.16 A compound according to Embodiment 1.5 or 1.8 wherein R 5 is selected from hydrogen; COCH3; non-aromatic C optionally substituted by one or more fluorine atoms 1-10 A hydrocarbon group, wherein C 1-10 Any atom of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S; the group -(CH2) n - aryl, wherein n is 0-3; or R 5 Can be used with R 6joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, wherein the optional substituents are selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or the C1-C3 alkoxy group may have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino.
[0064] 1.17 A compound according to Embodiment 1.5 or 1.8 wherein R 6 is selected from hydrogen; non-aromatic C optionally substituted by one or more fluorine atoms 1-10 A hydrocarbon group, wherein C 1-10 Any atom of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S; the group -(CH2) n - aryl, wherein n is 0-3; or R 6 Can be used with R 5 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, wherein the optional substituents are selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or the C1-C3 alkoxy group may have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino.
[0065] 1.18 A compound according to any one of Embodiments 1.1 to 1.17 wherein R 5 and R 6 independently selected from hydrogen, COCH3 and C 1-6 alkyl.
[0066] 1.19 A compound according to Embodiment 1.18 wherein R 5 and R 6 Independently selected from methyl, ethyl or methylcyclobutyl.
[0067] 1.20 A compound according to any one of Embodiments 1.1 to 1.17 wherein R 5 It's COCH3.
[0068] 1.21 A compound according to Embodiment 1.1, wherein R 7 It is a C1-C3 alkyl group.
[0069] 1.22 A compound according to Embodiment 1.1, wherein R 7 It is ethyl.
[0070] 1.23 A compound according to any one of Embodiments 1.1 to 1.22 wherein R2 is selected from hydrogen; fluorine; cyano; hydroxyl; amino; and C optionally substituted by one to six fluorine atoms 1-3 A hydrocarbon group, and wherein one of the carbon atoms of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S and their oxidized forms; or R 2 With R 1 Connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
[0071] 1.24 A compound according to any one of Embodiments 1.1 to 1.23 wherein R 2 It is hydrogen or cyano.
[0072] 1.25 A compound according to any one of Embodiments 1.1 to 1.24 wherein R 2 It's hydrogen.
[0073] 1.26 A compound according to any one of Embodiments 1.1 to 1.24 wherein R 2 It's cyano.
[0074] 1.27 A compound according to any one of Embodiments 1.1 to 1.23 wherein R 2 With R 1 are linked to form an optionally substituted spirocyclic group.
[0075] 1.28 Compounds according to Embodiment 1.1, wherein R 4 is hydrogen or C 1-6 Alkyl group or C 3-6 Cycloalkyl groups, wherein the alkyl groups and cycloalkyl groups are optionally substituted by one or more fluorine atoms, and wherein any one atom of the alkyl group or cycloalkyl group may be optionally replaced by an O heteroatom.
[0076] 1.29 Compounds according to Embodiment 1.1, wherein R 4 It's hydrogen.
[0077] 1.30 A compound according to Embodiment 1.1, wherein R 4 It's methyl.
[0078] 1.31 A compound according to Embodiment 1.1, wherein R 4 It is ethyl.
[0079] 1.32 A compound according to Embodiment 1.1, wherein R 4 is halogen, OH or CN.
[0080] 1.33 A compound according to Embodiment 1.1, wherein R4 is methyl, trifluoromethyl, ethyl, isopropyl or cyclopropyl.
[0081] 1.34 A compound according to any one of Embodiments 1.1 to 1.33 wherein X 1 and X 2 The ring system formed is selected from 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, 6-azabicyclo[3.2.1]octane, 7-azaspiro[3.4]octane, 2-azaspiro[3.4]octane, 6-azaspiro[3.3]heptane, 3-azabicyclo[3.1.1]heptane, 3-oxa-9-azabicyclo[3.3.1]nonane, 2-azabicyclo[2.2.2]octane, piperidine and azepane.
[0082] 1.35 A compound according to any one of Embodiments 1.1 to 1.33 wherein X 1 and X 2 The ring system formed is selected from:
[0083]
[0084] 1.36 A compound according to Embodiment 1.1, wherein X 3 and X 4 The ring system formed is selected from piperidine, azepane and 3-azabicyclo[3.1.0]hexane.
[0085] 1.37 A compound according to Embodiment 1.1, wherein X 3 and X 4 The ring system formed is selected from:
[0086]
[0087] 1.38 A compound according to Embodiment 1.36 wherein X 3 and X 4 The ring system formed is piperidine.
[0088] 1.39 A compound according to any one of Embodiments 1.1 to 1.38 having formula (2):
[0089]
[0090] or a salt thereof, wherein:
[0091] X 1 , X 2 , R 1 , R 2 and R 4 is defined according to any one of Embodiments 1.1 to 1.38.
[0092] 1.40 A compound according to any one of Embodiments 1.1 to 1.38 having formula (3):
[0093]
[0094] or a salt thereof, wherein:
[0095] X 1 , X 2 , R 1 , R 2 and R 4 is defined according to any one of Embodiments 1.1 to 1.38.
[0096] 1.41 A compound according to any one of Embodiments 1.1 to 1.38 having the formula (4):
[0097]
[0098] or a salt thereof, wherein:
[0099] X 1 , X 2 , R 1 , R 2 and R 4 is defined according to any one of Embodiments 1.1 to 1.38.
[0100] 1.42 A compound according to any one of Embodiments 1.1 to 1.41 selected from:
[0101] 2-(3-methyl-1,2,4-oxadiazol-5-yl)-6-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-2-azaspiro[3.3]heptane;
[0102] 6-(3-methyl-1,2,4-oxadiazol-5-yl)-2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane;
[0103] 1-[6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[3.4]octan-2-yl]-4-phenylpiperidine-4-carbonitrile;
[0104] (1R,5S,6r)-3-[6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[3.4]octan-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid ethyl ester;
[0105] 2-(3-methyl-1,2,4-oxadiazol-5-yl)-6-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-2-azaspiro[3.4]octane;
[0106] 1'-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(1H-pyrazol-1-yl)-1,4'-bipiperidine;
[0107] 3-(3-methyl-1,2,4-oxadiazol-5-yl)-6-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-azabicyclo[3.1.1]heptane;
[0108] 8-(3-methyl-1,2,4-oxadiazol-5-yl)-3-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-8-azabicyclo[3.2.1]octane;
[0109] 8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one;
[0110] 8-[8-(3-ethyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one;
[0111] 8-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0112] N-(1-methylcyclobutyl)-1-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]piperidine-4-carboxamide;
[0113] 2-(3-methyl-1,2,4-oxadiazol-5-yl)-5-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-2-azabicyclo[2.2.2]octane;
[0114] 9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-9-azabicyclo[3.3.1]nonane;
[0115] 8-[9-(3-methyl-1,2,4-oxadiazol-5-yl)-9-azabicyclo[3.3.1]nonan-3-yl]-2,8-diazaspiro[4.5]decan-3-one;
[0116] 8-[9-(3-methyl-1,2,4-oxadiazol-5-yl)-9-azabicyclo[3.3.1]nonan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0117] N-(1-methylcyclobutyl)-1-[9-(3-methyl-1,2,4-oxadiazol-5-yl)-9-azabicyclo[3.3.1]non-3-yl]piperidine-4-carboxamide;
[0118] 9-(3-methyl-1,2,4-oxadiazol-5-yl)-7-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane;
[0119] (1R,5S,6r)-N,N-diethyl-3-[9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]non-7-yl]-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0120] 1-(3-methyl-1,2,4-oxadiazol-5-yl)-4-[4-(1H-pyrazol-1-yl)piperidin-1-yl]azepane;
[0121] 8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-2,8-diazaspiro[4.5]decan-3-one;
[0122] 8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0123] 4-ethyl-8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0124] 4,4-dimethyl-8-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0125] 1'-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]spiro[indol-3,4'-piperidin]-2(1H)-one;
[0126] [(2R,4R)-4-Fluoro-1-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidin-2-yl]methanol;
[0127] [(2R)-4,4-difluoro-1-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidin-2-yl]methanol;
[0128] (5S)-5-ethyl-1-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidin-2-one;
[0129] 1-(3-methyl-1,2,4-oxadiazol-5-yl)-4-{4-[2-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl]piperidin-1-yl}azepane;
[0130] N-ethyl-N-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}acetamide;
[0131] (2S)-N-methyl-2-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidine-1-carboxamide;
[0132] 6-(3-methyl-1,2,4-oxadiazol-5-yl)-3-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azabicyclo[3.2.1]octane;
[0133] 8-[6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl]-2,8-diazaspiro[4.5]decan-3-one;
[0134] 8-[6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0135] 8-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0136] 8-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0137] 8-(8-(3-(Trifluoromethyl)-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0138] 8-(8-(3-(Trifluoromethyl)-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0139] (1R,5S,6r)-3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.4]octan-6-yl)-N-(1-methylcyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0140] 1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-(trifluoromethyl)cyclobutyl)piperidine-4-carboxamide;
[0141] N-(1-ethylcyclobutyl)-1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidine-4-carboxamide;
[0142] N-(1-isopropylcyclobutyl)-1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidine-4-carboxamide;
[0143] 1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-methylcyclopentyl)piperidine-4-carboxamide;
[0144] 1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-((1-methylcyclobutyl)methyl)piperidine-4-carboxamide;
[0145] (1R,5S,6r)-3-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-methylcyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0146] N-(1-methylcyclobutyl)-1-(8-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidine-4-carboxamide;
[0147] 1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-N-(1-methylcyclobutyl)piperidine-4-carboxamide;
[0148] 1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-N-((1-methylcyclobutyl)methyl)piperidine-4-carboxamide;
[0149] N-(1-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]non-7-yl)piperidin-4-yl)-N-((1-methylcyclobutyl)methyl)acetamide;
[0150] N-(1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-N-((1-methylcyclobutyl)methyl)acetamide;
[0151] N-(1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)piperidin-4-yl)-N-((1-methylcyclobutyl)methyl)acetamide;
[0152] N-Benzyl-N-(1-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)piperidin-4-yl)acetamide;
[0153] ((1R,5S,6r)-3-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]non-7-yl)-3-azabicyclo[3.1.0]hex-6-yl)(1-azaspiro[3.3]hept-1-yl)methanone;
[0154] (1R,5S,6r)-N-isopropyl-N-methyl-3-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0155] (1R,5S,6r)-N,N-diethyl-3-(9-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0156] (1R,5S,6r)-N-ethyl-N-methyl-3-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0157] (1R,5S,6r)-N,N-diethyl-3-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0158] (1R,5S,6r)-N,N-diethyl-3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.4]octan-6-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0159] (1R,5S,6r)-N-ethyl-N-methyl-3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.4]octan-6-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0160] N,N-diethyl-1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.4]octan-6-yl)piperidine-4-carboxamide;
[0161] 8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.6]undecan-3-one;
[0162] 8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.6]undecan-2-one;
[0163] 8-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-2,8-diazaspiro[4.6]undecan-3-one;
[0164] 8-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-1-oxa-3,8-diazaspiro[4.6]undecan-2-one;
[0165] 8-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.6]undecan-3-one;
[0166] 8-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.6]undecan-2-one;
[0167] ((1R,5S,6r)-3-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)(1-azaspiro[3.3]hept-1-yl)methanone;
[0168] (1R,5S,6r)-N,N-diethyl-3-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0169] (1R,5S,6r)-N-ethyl-N-isopropyl-3-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]oct-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0170] (1R,5S,6r)-N-isopropyl-N-methyl-3-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0171] (1R,5S,6r)-N-ethyl-N-methyl-3-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-9-azabicyclo[3.3.1]nonan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0172] (1R,5S,6r)-N,N-diethyl-3-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-9-azabicyclo[3.3.1]nonan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0173] 8-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)azepan-4-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0174] 8-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)azepan-4-yl)-2,8-diazaspiro[4.6]undecan-3-one;
[0175] 8-(1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl)-2,8-diazaspiro[4.6]undecan-3-one;
[0176] 8-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)azepan-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0177] 8-(8-(3-ethyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0178] 8-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0179] 8-(6-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)-6-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0180] 4-methyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0181] (1R,5S,6r)-3-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[3.4]octan-2-yl)-N-(1-methylcyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0182] N-(1-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[3.4]octan-2-yl)piperidin-4-yl)-N-((1-methylcyclobutyl)methyl)acetamide;
[0183] N-(1-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]non-7-yl)piperidin-4-yl)-N-((1-methylcyclobutyl)methyl)acetamide;
[0184] N-(1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-N-((1-methylcyclobutyl)methyl)acetamide;
[0185] (1R,5S,6r)-N-isopropyl-N-methyl-3-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0186] (1R,5S,6r)-N-ethyl-N-methyl-3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]oct-5-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0187] (1R,5S,6r)-N-ethyl-N-methyl-3-(9-(3-methyl-1,2,4-oxadiazol-5-yl)-9-azabicyclo[3.3.1]nonan-3-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0188] 8-(1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0189] 8-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)azepan-4-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0190] 8-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)azepan-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0191] 8-(8-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0192] 8-(8-(3-isopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0193] 8-(8-(3-ethyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0194] 4-Benzyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0195] 1-isopropyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0196] 4-isopropyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0197] 1-Cyclopropyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0198] 8-(8-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0199] 8-(8-(3-isopropyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0200] N-Benzyl-N-(1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)acetamide;
[0201] (1R,5S,6r)-N,N-diethyl-3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]hept-6-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0202] ((1R,5S,6r)-3-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[3.4]octan-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)(1-azaspiro[3.3]hept-1-yl)methanone;
[0203] Azepan-1-yl(1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)methanone;
[0204] 1-(Cyclopropylmethyl)-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0205] 4-(Cyclopropylmethyl)-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0206] 4-cyclopropyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0207] 1-Benzyl-8-(6-(3-methyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[3.4]octan-2-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0208] 4-Benzyl-8-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]hept-6-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;
[0209] 1-Benzyl-8-(1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0210] 8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.6]undecan-3-one;
[0211] 1-Benzyl-8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2,8-diazaspiro[4.5]decan-3-one;
[0212] 8-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-1-oxa-3,8-diazaspiro[4.6]undecan-2-one;
[0213] (1R,5S,6r)-3-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-(trifluoromethyl)cyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0214] (1R,5S,6r)-3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azabicyclo[2.2.2]octan-5-yl)-N-(1-(trifluoromethyl)cyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;
[0215] or a salt thereof.
[0216] 1.43 A compound according to Embodiment 1.1 which is defined as in any one of Embodiments 1-1 to 18-2.
[0217] 1.44 A compound according to any one of Embodiments 1.1 to 1.43 having a molecular weight of less than 550, for example less than 500 or less than 450.
[0218] 1.45 A compound according to any one of Embodiments 1.1 to 1.44 which is in the form of a salt.
[0219] 1.46 A compound according to Embodiment 1.45 wherein the salt is an acid addition salt.
[0220] 1.47 A compound according to Embodiment 1.45 or Embodiment 1.46 wherein the salt is a pharmaceutically acceptable salt.
[0221] In some embodiments, R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 ; an optionally substituted 5- or 6-membered ring containing 0, 1 or 2 nitrogen heteroatoms; or R 1 With R 2 Connected to form an optionally substituted monocyclic or bicyclic ring.
[0222] In some embodiments, R 1 With R 2 Connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1 or 2 heteroatoms selected from O or N.
[0223] In some embodiments, R 1 With R 2 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1 or 2 heteroatoms selected from O or N, wherein the optional substituents are selected from C1-C6 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl, amino or a group -(CH2) n -aryl, wherein n is 0-3.
[0224] In some embodiments, R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ; or COOR 7 .
[0225] In some embodiments, R 1is an optionally substituted 5- or 6-membered ring containing 0, 1 or 2 nitrogen heteroatoms, wherein the optional substituents are selected from C1-C3 alkyl, C1-C3 alkoxy, CONR 5 R 6 , halogen, cyano, oxo, hydroxy, amino or an optionally substituted heterocycle containing 1 or 2 heteroatoms selected from O or N, wherein the optional substituent is C1-C3 alkyl.
[0226] In some embodiments, R 2 It is H or cyano.
[0227] In some embodiments, R 1 Selected from NR 5 R 6 ,CONR 5 R 6 or COOR 7 , and R 5 Selected from COCH3, non-aromatic C 1-6 A hydrocarbon group, or R 5 Can be used with R 6 Joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
[0228] In some embodiments, R 5 Selected from COCH3, non-aromatic C 1-6 A hydrocarbon group, or R 5 Can be used with R 6 Joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino.
[0229] In some embodiments, wherein R 6 Selected from hydrogen, non-aromatic C 1-6 A hydrocarbon group, or R 6 Can be used with R 5 are joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or the C1-C3 alkoxy group can have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino.
[0230] In some embodiments, R 1 It is COOR 7 , and R 7 It is a C1-C3 alkyl group.
[0231] In some embodiments, R4 is methyl, trifluoromethyl, ethyl, isopropyl or cyclopropyl.
[0232] In some embodiments, the compounds herein as defined above are used in medicine.
[0233] In some embodiments, the present application provides a pharmaceutical composition comprising a compound as defined above and a pharmaceutically acceptable excipient.
[0234] In some embodiments, the compounds as defined above have muscarinic M1 and / or M4 receptor agonist activity.
[0235] definition
[0236] In this application, the following definitions apply unless indicated otherwise.
[0237] With respect to the use of compounds of Formula (1), (1a), (2), (3), or (4), the term "treatment" is used to describe any form of intervention in which the compound is administered to a subject suffering from, at risk of, or potentially at risk of the disease or disorder in question. Thus, the term "treatment" encompasses both preventative (prophylactic) treatment and treatment where measurable or detectable symptoms of a disease or disorder are being exhibited.
[0238] As used herein, the term "therapeutically effective amount" (e.g., with respect to a treatment method for a disease or condition) refers to an amount of a compound that is effective to produce the desired therapeutic effect. For example, if the condition is pain, the therapeutically effective amount is an amount sufficient to provide a desired level of pain relief. The desired level of pain relief can be, for example, complete elimination of pain or a reduction in the severity of pain.
[0239] Unless otherwise indicated, the terms "alkyl," "heterocycle," and "ether" are used in their conventional sense (eg, as defined in the IUPAC Gold Book).
[0240] As used herein, the term "monocyclic" refers to an arrangement of atoms arranged in a manner to form a monocyclic structure. As used herein, the term "bicyclic" refers to an arrangement of atoms arranged in a manner to form two joined rings. Bicyclic compounds can be carbocyclic or heterocyclic. In addition, both rings can be aliphatic, or can be aromatic, or a combination of aliphatic and aromatic.
[0241] In the above X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R4 , R 5 , R 6 or R 7 In the definition of, in the case of the statement, one or two but not all carbon atoms of the non-aromatic hydrocarbon group or alkyl group or cycloalkyl group can be optionally replaced by heteroatoms selected from O and N. In the case where the group is a single carbon (C1) group, carbon cannot be replaced. It should be understood that when a carbon atom is replaced by a heteroatom, the lower valence of the heteroatom compared to carbon means that the atom that will be bonded to the heteroatom is less than the atom that will be bonded to the carbon atom that has been replaced. Therefore, for example, replacing a carbon atom (valence of 4) in a CH2 group by oxygen (valence of 2) will mean that the resulting molecule will contain two fewer hydrogen atoms, and replacing a carbon atom (valence of 4) in a CH2 group by nitrogen (valence of 3) will mean that the resulting molecule will contain one less hydrogen atom.
[0242] Examples of heteroatom replacements for carbon atoms include replacement of carbon atoms in a -CH2-CH2-CH2- chain with oxygen or sulfur to give an ether -CH2-O-CH2- or a thioether -CH2-S-CH2-, replacement of a carbon atom in a group CH2-C≡CH with nitrogen to give a nitrile (cyano) group CH2-C≡N, replacement of a carbon atom in a group -CH2-CH2-CH2- with C=O to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH2-CH2- with S=O or SO2 ... S=O or SO2 to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH2-CH2- with S=O or SO2 to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH2-CH2- with S=O or SO2 to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group - To give a sulfoxide -CH2-S(O)-CH2- or a sulfone -CH2-S(O)2-CH2-, to replace a carbon atom in a -CH2-CH2-CH2- chain with C(O)NH to give an amide -CH2-CH2-C(O)-NH-, to replace a carbon atom in a -CH2-CH2-CH2- chain with nitrogen to give an amine -CH2-NH-CH2-, and to replace a carbon atom in a -CH2-CH2-CH2- chain with C(O)O to give an ester (or carboxylic acid) -CH2-CH2-C(O)-O-. In each such substitution, at least one carbon atom in the hydrocarbon group must be retained.
[0243] Salt
[0244] Many compounds of formula (1), (1a), (2), (3) or (4) may exist in the form of salts, for example acid addition salts or, in certain cases, salts of organic and inorganic bases such as carboxylates, sulfonates and phosphates. All such salts are within the scope of the invention and references to compounds of formula (1), (1a), (2), (3) or (4) include salt forms of the compounds as defined in Embodiments 1.40 to 1.47.
[0245] The salt is typically an acid addition salt.
[0246] The salts of the present invention can be synthesized from a parent compound containing a basic or acidic moiety by conventional chemical methods such as those described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (ed.), Camille G. Wermuth (ed.), ISBN: 3-90639-026-8, Hardcover, p. 388, August 2002. Typically, such salts can be prepared by reacting the free acid or free base forms of these compounds with an appropriate base or acid in water or an organic solvent or a mixture of the two; typically using a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
[0247] Acid addition salts (as defined in Embodiment 1.46) can be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts falling within Embodiment 1.46 include mono- or di-salts formed with an acid selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, decanoic acid, hexanoic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, mucic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-ketoglutaric acid (α-oxoglutaric acid), acid), glycolic acid, hippuric acid, hydrohalic acids (e.g., hydrobromic acid, hydrochloric acid, hydroiodic acid), isethionic acid, lactic acid (e.g., (+)-L-lactic acid, (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyruvic acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid, and valeric acid, as well as acylated amino acids and cation exchange resins.
[0248] In the case where the compounds of formula (1), (1a), (2), (3) or (4) contain amine functional groups, these can be reacted with an alkylating agent to form a quaternary ammonium salt, for example, according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of formula (1), (1a), (2), (3) or (4).
[0249] The compounds of the present invention may exist as mono- or di-salts depending on the pKa of the acid forming the salt.
[0250] The salt forms of the compounds of the present invention are generally pharmaceutically acceptable salts, and examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19. However, non-pharmaceutically acceptable salts may also be prepared as intermediate forms, which may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salt forms, which may be useful, for example, in the purification or isolation of the compounds of the present invention, also form part of the present invention.
[0251] Stereoisomers
[0252] Stereoisomers are isomeric molecules that have the same molecular formula and sequence of bonded atoms but differ only in the three-dimensional orientation of their atoms in space. Stereoisomers may be, for example, geometric isomers or optical isomers.
[0253] Geometric isomers
[0254] In the case of geometric isomers, the isomerism is due to different orientations of atoms or groups about a double bond, such as cis and trans (Z and E) isomerism around a carbon-carbon double bond, or cis and trans isomerism around an amide bond, or cis and trans isomerism around a carbon-nitrogen double bond (for example in oximes), or rotational isomerism around a bond about which there is restricted rotation, or cis and trans isomerism around a ring such as a cycloalkane ring.
[0255] Thus, in another embodiment (Embodiment 1.48), the invention provides a geometric isomer of a compound according to any one of Embodiments 1.1 to 1.47.
[0256] Optical isomers
[0257] Where compounds of the formula contain one or more chiral centers and can exist in two or more optical isomeric forms, reference to the compound includes all optical isomeric forms thereof (e.g., enantiomers, epimers and diastereomers), either as individual optical isomers or as mixtures (e.g., racemic mixtures) or two or more optical isomers, unless the context requires otherwise.
[0258] Thus, in another embodiment (Embodiment 1.49), the invention provides a compound according to any one of Embodiments 1.1 to 1.48 comprising a chiral center.
[0259] Optical isomers can be characterized and identified by their optical activity (i.e., as + and - isomers, or d and l isomers) or they can be characterized by their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, see Jerry March, Advanced Organic Chemistry, 4th edition, John Wiley & Sons, New York, 1992, pages 109-114, and also see Cahn, Ingold & Prelog, Angew. Chem. Int. Ed. Engl., 1966, 5, 385-415. Optical isomers can be separated by a number of techniques including chiral chromatography (chromatography on a chiral support), and such techniques are well known to those skilled in the art. As an alternative to chiral chromatography, optical isomers can be separated by forming diastereomeric salts with chiral acids such as (+)-tartaric acid, (-)-pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid and (-)-camphorsulfonic acid, separating the diastereomers by preferential crystallization and then dissociating the salts to give the individual enantiomers of the free base.
[0260] Where the compounds of the invention exist as two or more optical isomeric forms, one enantiomer of a pair of enantiomers may, for example, exhibit an advantage over the other enantiomer in terms of biological activity. Thus, in certain circumstances, it may be desirable to use only one of a pair of enantiomers or only one of more than one diastereomer as a therapeutic agent.
[0261] Thus, in another embodiment (Embodiment 1.50), the invention provides a composition comprising a compound according to Embodiment 1.49 having one or more chiral centers, wherein at least 55% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%) of the compound of Embodiment 1.44 exists as a single optical isomer (e.g., enantiomer or diastereomer).
[0262] In one general embodiment (Embodiment 1.51), 99% or more (e.g. substantially all) of the total amount of the compounds of Embodiment 1.49 (or the compounds for use of Embodiment 1.49) is present as a single optical isomer.
[0263] For example, in one embodiment (Embodiment 1.52), the compound exists as a single enantiomer.
[0264] In another embodiment (Embodiment 1.53), the compound exists as a single diastereomer.
[0265] The present invention also provides a mixture of optical isomers which may be racemic or non-racemic. Therefore, the present invention provides:
[0266] 1.54 A compound according to Embodiment 1.49 which is in the form of a racemic mixture of optical isomers.
[0267] 1.55 A compound according to Embodiment 1.49 which is in the form of a non-racemic mixture of optical isomers.
[0268] isotope
[0269] The compounds of the invention as defined in any one of Embodiments 1.1 to 1.55 may contain one or more isotopic substitutions, and references to a particular element include within its scope all isotopes of that element. For example, references to hydrogen include 1 H. 2 H(D) and 3 H(T) is included within its scope. Similarly, references to carbon and oxygen will be 12 C. 13 C and 14 C and 16 O and 18 O is included in their scope.
[0270] In a similar manner, reference to a particular functional group also includes isotopic variations within its scope unless the context indicates otherwise. For example, reference to an alkyl group such as an ethyl group also encompasses variations in which one or more hydrogen atoms in the group are in the form of deuterium or tritium isotopes, for example, as in an ethyl group in which all five hydrogen atoms are in the form of deuterium isotopes (perdeuterated ethyl group).
[0271] Isotopes may be radioactive or non-radioactive. In one embodiment of the invention (Embodiment 1.56), the compound described in any one of Embodiments 1.1 to 1.53 does not contain a radioactive isotope. Such compounds are preferably used for therapeutic purposes. However, in another embodiment (Embodiment 1.57), the compound described in any one of Embodiments 1.1 to 1.55 may contain one or more radioactive isotopes. Compounds containing such radioactive isotopes may be useful in a diagnostic context.
[0272] Solvate
[0273] Compounds of formula (1), formula (1a), formula (2), formula (3) or formula (4) as defined in any one of Embodiments 1.1 to 1.57 may form solvates. Preferred solvates are solvates formed by incorporating molecules of a non-toxic pharmaceutically acceptable solvent (hereinafter referred to as a solvating solvent) into the solid state structure (e.g., crystal structure) of the compound of the invention. Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethyl sulfoxide. Solvates may be prepared by recrystallizing the compound of the invention with a solvent or a solvent mixture containing a solvating solvent. Whether a solvate has been formed in any given case may be determined by subjecting the crystals of the compound to analysis using well-known and standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography. Solvates may be stoichiometric or non-stoichiometric solvates. Particularly preferred solvates are hydrates, and examples of hydrates include hemihydrates, monohydrates and dihydrates.
[0274] Thus, in further embodiments 1.58 and 1.59, the invention provides:
[0275] 1.58 A compound according to any one of Embodiments 1.1 to 1.57 in the form of a solvate.
[0276] 1.59 A compound according to Embodiment 1.58 wherein the solvate is a hydrate.
[0277] For a more detailed discussion of solvates and methods for preparing and characterizing them, see Bryn et al., Solid-State Chemistry of Drugs, 2nd edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.
[0278] Alternatively, the compounds of the invention may be anhydrous rather than existing as hydrates. Thus, in another embodiment (Embodiment 1.60), the invention provides a compound as defined in any one of Embodiments 1.1 to 1.58 in an anhydrous form (eg an anhydrous crystalline form).
[0279] Crystalline and amorphous forms
[0280] The compound described in any one of Embodiments 1.1 to 1.60 can exist in a crystalline or non-crystalline (e.g., amorphous) state. Whether a compound exists in a crystalline state can be easily determined by standard techniques such as X-ray powder diffraction (XRPD). Crystals and their crystal structures can be characterized using a number of techniques, including single crystal X-ray crystallography, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared spectroscopy such as Fourier transform infrared spectroscopy (FTIR). The behavior of crystals under different humidity conditions can be studied by weight vapor sorption and also analyzed by XRPD. The determination of the crystal structure of the compound can be carried out by X-ray crystallography which can be carried out according to conventional methods, such as those described herein and as described in Fundamentals of Crystallography, C. Giacovazzo, HL Monaco, D. Viterbo, F. Scordari, G. Gilli, G. Zanotti and M. Catti, (International Union of Crystallography / Oxford University Press, 1992 ISBN 0-19-855578-4 (p / b), 0-19-85579-2 (h / b)). This technique involves the analysis and interpretation of X-ray diffraction of single crystals. In amorphous solids, there is no three-dimensional structure that is usually present in crystalline form, and the positions of the molecules relative to each other in the amorphous form are essentially random, see, for example, Hancock et al. J. Pharm. Sci. (1997), 86, 1).
[0281] Therefore, in further embodiments, the present invention provides:
[0282] 1.61 A compound according to any one of Embodiments 1.1 to 1.60 in crystalline form.
[0283] 1.62 A compound according to any one of Embodiments 1.1 to 1.61 which is:
[0284] (a) from 50% to 100% crystalline, and more particularly at least 50% crystalline, or at least 60% crystalline, or at least 70% crystalline, or at least 80% crystalline, or at least 90% crystalline, or at least 95% crystalline, or at least 98% crystalline, or at least 99% crystalline, or at least 99.5% crystalline, or at least 99.9% crystalline, for example 100% crystalline.
[0285] 1.63 A compound according to any one of Embodiments 1.1 to 1.62 which is in amorphous form.
[0286] Prodrug
[0287] The compounds of formula (1), (1a), (2), (3) or (4) as defined in any one of Embodiments 1.1 to 1.60 may be presented in the form of a prodrug. "Prodrug" means any compound that is converted in vivo into a biologically active compound of formula (1), (1a), (2), (3) or (4) as defined in any one of Embodiments 1.1 to 1.60.
[0288] For example, some prodrugs are esters of active compounds (e.g., physiologically acceptable metabolically labile esters). During metabolism, the ester group (-C(=O)OR) is cleaved to produce the active drug. Such esters can be formed, for example, by esterification of any hydroxyl groups present in the parent compound, where appropriate, any other reactive groups present in the parent compound are pre-protected and subsequently deprotected as desired.
[0289] In addition, some prodrugs are enzymatically activated to produce the active compound, or the compound produces the active compound after further chemical reaction (e.g., as in ADEPT, GDEPT, LIDEPT, etc.). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an ester derivative of an amino acid.
[0290] Thus, in another embodiment (Embodiment 1.64), the invention provides a prodrug of a compound as defined in any one of Embodiments 1.1 to 1.60, wherein the compound contains a functional group which is convertible under physiological conditions to form a hydroxyl group or an amino group.
[0291] Complexes and inclusion compounds
[0292] Formula (1), (1a), (2), (3) or (4) in Embodiments 1.1 to 1.64 also encompass complexes of the compounds of Embodiments 1.1 to 1.64 (e.g., inclusion complexes or inclusion complexes with compounds such as cyclodextrins, or complexes with metals).
[0293] Thus, in another embodiment (Embodiment 1.65), the invention provides a compound according to any one of Embodiments 1.1 to 1.64 in the form of a complex or inclusion compound.
[0294] Biological activity and therapeutic uses
[0295] The compounds of the invention have activity as muscarinic M1 and / or M4 receptor agonists.The muscarinic activity of the compounds can be determined using the phospho-ERK1 / 2 assay described in Example A below.
[0296] A significant advantage of the compounds of the present invention is that they are highly selective for M1 and / or M4 receptors relative to M2 and M3 receptor subtypes. The compounds of the present invention are neither agonists nor antagonists of M2 and M3 receptor subtypes. For example, given that the compounds of the present invention generally have a pEC of at least 6 (preferably at least 6.5) for the M1 receptor in the functional assay described in Example A, 50 value and an E greater than 80 (preferably greater than 95) max Values, when tested against M2 and M3 subtypes in the functional assay of Example A, the compounds of the invention may have a pEC value of less than 5 50 value and less than 20% of E max value.
[0297] Some compounds of the invention are active at both the M1 and M4 receptors.
[0298] Thus, in embodiments 2.1 to 2.17, the present invention provides:
[0299] 2.1 A compound according to any one of Embodiments 1.1 to 1.65 for use in medicine.
[0300] 2.2 A compound according to any one of Embodiments 1.1 to 1.65 for use as a muscarinic M1 and / or M4 receptor agonist.
[0301] 2.3 A compound according to any one of Embodiments 1.1 to 1.65, which has a pEC of greater than 6.9 for the M1 receptor in an assay of Example A herein or an assay substantially similar thereto. 50 and an E of at least 80 max A muscarinic M1 receptor agonist.
[0302] 2.4 A compound according to Embodiment 2.3, which has a pEC greater than 7.0 50 A muscarinic M1 receptor agonist.
[0303] 2.5 A compound according to Embodiment 2.3 or Embodiment 2.4 having an E of at least 90 for the M1 receptor max .
[0304] 2.6 A compound according to any one of Embodiments 1.1 to 1.65, which has a pEC in the range of from 6.0 to 8.7 for the M4 receptor in an assay of Example A herein or an assay substantially similar thereto. 50 and at least 60 E max Agonists of the muscarinic M1 and / or M4 receptors.
[0305] 2.7 A compound according to any one of Embodiments 1.1 to 1.65, which has a pEC in the range of from 6.0 to 8.1 for the M4 receptor in an assay of Example A herein or an assay substantially similar thereto. 50 and an E of at least 90 max Agonists of the muscarinic M1 and / or M4 receptors.
[0306] 2.8 A compound according to Embodiment 2.6, which has a pEC in the range of from 7.5 to 8.7 50 A muscarinic M4 receptor agonist.
[0307] 2.9 The compound according to Embodiment 2.7, which has a pEC in the range of from 6.5 to 7.5. 50 A muscarinic M4 receptor agonist.
[0308] 2.10 A compound according to Embodiment 2.6 or Embodiment 2.8 having an E of at least 75 for the M4 receptor max .
[0309] 2.11 A compound according to Embodiment 2.7 or Embodiment 2.9 having an E of at least 95 for the M4 receptor max .
[0310] 2.12 A compound according to any one of Embodiments 2.3 to 2.11 which is selective for M1 and M4 receptors compared to muscarinic M2 and M3 receptors.
[0311] 2.13 A compound according to Embodiment 2.12 which is selective for the M1 receptor over the muscarinic M2 and M3 receptors.
[0312] 2.14 A compound according to any one of Embodiments 2.3 to 2.5 which is selective for the Ml receptor over the muscarinic M2, M3 and M4 receptors.
[0313] 2.15 A compound according to any one of Embodiments 2.3 to 2.14 having a pEC of less than 5 for muscarinic M2 and M3 receptor subtypes. 50 and E less than 50max .
[0314] 2.16 A compound according to Embodiment 2.15 having a pEC of less than 4.5 for muscarinic M2 and M3 receptor subtypes 50 and / or E less than 30 max .
[0315] 2.17 A compound according to any one of Embodiments 1.1 to 1.65 and Embodiments 2.3 to 2.16 for use in treating a disease or condition mediated by the muscarinic M1 receptor.
[0316] Due to their muscarinic M1 and / or M4 receptor agonist activity, the compounds of the present invention can be used to treat Alzheimer's disease, schizophrenia and other psychotic disorders, cognitive disorders and other diseases mediated by muscarinic M1 and / or M4 receptors, and can also be used to treat various types of pain.
[0317] Thus, in Embodiments 2.18 to 2.39, the present invention provides:
[0318] 2.18 A compound according to any one of Embodiments 1.1 to 1.65 for use in treating a cognitive disorder or a psychotic disorder.
[0319] 2.19 A compound for use according to Embodiment 2.18 wherein the cognitive disorder or psychotic disorder comprises or is caused by or is associated with a condition selected from the group consisting of cognitive impairment, mild cognitive impairment (including mild cognitive impairment due to Alzheimer's disease and / or prodromal Alzheimer's disease), frontotemporal dementia, vascular dementia, dementia with Lewy bodies, presenile dementia, senile dementia, Friederich's ataxia, Down syndrome, Huntington's disease, hyperkinesia, mania, Tourette syndrome, Alzheimer's disease (including those described in the "Early Alzheimer's disease: Developing Drugs for Treatment” as defined in the “Dementia Treatment”, prodromal Alzheimer’s disease and early Alzheimer’s disease stages 1, 2, and 3), progressive supranuclear palsy, impairment of cognitive function including attention, orientation, learning impairment, memory (i.e., memory impairment, amnesia, amnesic disorder, transient global amnesia syndrome, and age-related memory impairment), and language function; cognitive impairment due to stroke, Huntington’s disease, Pick’s disease, AIDS-related dementia or other dementing states such as multi-infarct dementia, alcoholic dementia, dementia associated with hypothyroidism, and dementia associated with other degenerative disorders such as cerebellar atrophy and amyotrophic lateral sclerosis; other acute or subacute conditions that can lead to cognitive impairment such as delirium or depression (pseudo-dementia state) trauma, head trauma, age-related cognitive impairment, stroke, neurodegeneration, drug-induced states, neurotoxic agents, age-related cognitive impairment, cognitive impairment associated with autism, Down syndrome, Cognitive deficits associated with psychosis, and cognitive impairment associated with electroconvulsive therapy; cognitive impairment due to drug abuse or withdrawal including nicotine, marijuana, amphetamines, cocaine, attention deficit hyperactivity disorder (ADHD) and movement disorders such as Parkinson's disease, neuroleptic-induced Parkinson's disease and tardive dyskinesia, schizophrenia, schizophreniform disorders, psychotic depression, mania, acute mania, paranoid, hallucinogenic and delusional disorders, personality disorders, obsessive-compulsive disorder, schizotypal disorder, delusional disorder, psychosis due to malignancy, metabolic disorders, endocrine diseases or hypersomnia, psychosis due to drug abuse or withdrawal, bipolar disorder, and schizoaffective disorder.
[0320] 2.20 A compound according to any one of Embodiments 1.1 to 1.65 for use in treating Alzheimer's disease.
[0321] 2.21 A compound according to any one of Embodiments 1.1 to 1.65 for use in treating schizophrenia.
[0322] 2.22 A method of treating a cognitive disorder in a subject (eg, a mammalian patient such as a human, eg, a human in need of such treatment), the method comprising administering a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.65.
[0323] 2.23 A method according to Embodiment 2.22 wherein the cognitive impairment comprises, is caused by or is associated with a condition as defined in Embodiment 2.17.
[0324] 2.24 A method according to Embodiment 2.23 wherein the cognitive impairment is caused by or is associated with Alzheimer's disease.
[0325] 2.25 A method according to Embodiment 2.23 wherein the cognitive disorder is schizophrenia.
[0326] 2.26 Use of a compound according to any one of Embodiments 1.1 to 1.65 for the manufacture of a medicament for the treatment of a cognitive disorder.
[0327] 2.27 The use according to Embodiment 2.26 wherein the cognitive impairment comprises, is caused by or is associated with a condition as defined in Embodiment 2.19.
[0328] 2.28 The use according to Embodiment 2.27 wherein the cognitive impairment is caused by or is associated with Alzheimer's disease.
[0329] 2.29 The use according to Embodiment 2.28 wherein the cognitive disorder is schizophrenia.
[0330] 2.30 A compound according to any one of Embodiments 1.1 to 1.65 for use in treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postoperative pain or cancer pain.
[0331] 2.31 A method of treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postoperative pain or cancer pain, comprising administering a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.65.
[0332] 2.32 A compound according to any one of Embodiments 1.1 to 1.65 for use in treating a peripheral disorder such as reducing intraocular pressure in glaucoma and treating dry eyes and dry mouth including Sjögren's syndrome.
[0333] 2.33 A method of treating a peripheral disorder such as reducing intraocular pressure in glaucoma and treating dry eyes and dry mouth, including Sjögren's syndrome, comprising administering a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.65.
[0334] 2.34 Use of a compound according to any one of Embodiments 1.1 to 1.65 for the manufacture of a medicament for treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, post-operative pain or cancer pain, or for the manufacture of a medicament for treating peripheral disorders such as reducing intraocular pressure in glaucoma and treating dry eyes and dry mouth, including Sjögren's syndrome.
[0335] 2.35 Use of a compound according to any one of Embodiments 1.1 to 1.65 for treating skin lesions, for example due to pemphigus vulgaris, dermatitis herpetiformis, pemphigoid and other blistering skin conditions.
[0336] 2.36 Use of a compound according to any one of Embodiments 1.1 to 1.65 for treating, preventing, ameliorating or reversing conditions associated with altered gastrointestinal function and motility, such as symptoms of functional dyspepsia, irritable bowel syndrome, gastroesophageal acid reflux (GER) and esophageal dysmotility, gastroparesis and chronic diarrhea.
[0337] 2.37 Use of a compound according to any one of Embodiments 1.1 to 1.65 for treating olfactory dysfunction such as Bosma-Henkin-Christiansen syndrome, chemical poisoning (eg, selenium and silver), hypopituitarism, Kallmann syndrome, skull fractures, tumor therapy and underactive thyroid.
[0338] 2.38 Use of a compound according to any one of Embodiments 1.1 to 1.65 for treating addiction.
[0339] 2.39 Use of a compound according to any one of Embodiments 1.1 to 1.65 for treating movement disorders such as Parkinson's disease, ADHD, Huntington's disease, Tourette's syndrome and other syndromes associated with dopaminergic dysfunction as an underlying pathogenic factor driving the disease.
[0340] 2.40 Use of a compound according to any one of Embodiments 1.1 to 1.65 for treating behavioral and psychological symptoms of dementia (BPSD; including agitation, verbal aggression, physical aggression, depression, anxiety, abnormal motor behavior, elevated mood, dysphoria, apathy, disinhibition, impulsivity, delusions, hallucinations, sleep changes and appetite changes).
[0341] Method for preparing a compound of formula (1) or formula (2)
[0342] Compounds of formula (1), formula (1a), formula (2), formula (3) or formula (4) can be prepared according to synthetic methods well known to the skilled artisan and as described herein.
[0343] Thus, in another embodiment (Embodiment 3.1), the present invention provides a process for preparing a compound as defined in any one of Embodiments 1.1 to 1.65, the process comprising:
[0344] (A) making a compound of formula (10):
[0345]
[0346] With the compound of formula (11):
[0347]
[0348] Reaction under reductive amination conditions; where R 1 , R 2 , R 4 , X 1 , X 2 , X 3 and X 4 is defined in accordance with any one of Embodiments 1.1 to 1.65; or
[0349] (B) When it is necessary to prepare 1 Includes CONR 5 R 6 When the compound of formula (1) is:
[0350] The compound of formula (12):
[0351]
[0352] With formula R 5 R 6 NH amine reaction; wherein R represents a suitable group such as methyl or ethyl, and R 2 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 and X 4 is defined in accordance with any one of Embodiments 1.1 to 1.65; or
[0353] (C) When it is necessary to prepare 1 Includes CONR 5 R 6 When the compound of formula (1) is:
[0354] The compound of formula (13):
[0355]
[0356] With formula R 5 R 6 NH amine reaction; wherein R represents a suitable group such as methyl or ethyl, and R 2 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 and X 4 is defined in accordance with any one of Embodiments 1.1 to 1.65; or
[0357] (D) When it is necessary to prepare 1 When the compound of formula (1) includes a 5-membered or 6-membered ring containing a N(C=O)OR or N(C=O)NR2 group:
[0358] Make an amine of formula (14):
[0359]
[0360] Reaction with a compound of formula (15) or formula (16):
[0361]
[0362] Where R 2 , R 4 , X 1 , X 2 , X 3 and X 4 is defined according to any one of Embodiments 1.1 to 1.65, and LG represents a suitable leaving group such as C1, 1-imidazole or 4-nitrophenol; or
[0363] and optionally:
[0364] (E) converting a compound of formula (1) into another compound of formula (1).
[0365] In process variant (A), ketone (11) is reacted with amine (10) under reductive amination conditions. The reductive amination reaction is generally carried out at ambient temperature to mild heating (e.g., at a temperature of about 20°C to about 70°C) using a borohydride reducing agent such as sodium triacetoxyborohydride (STAB) in a solvent such as dichloromethane (DCM), dichloroethane (DCE), N,N-dimethylformamide (DMF) or methanol (MeOH) containing an acid such as acetic acid (AcOH) or trifluoroacetic acid (TFA), or sodium cyanoborohydride (NaCNBH3) in combination with zinc chloride (ZnCl2) in a solvent such as MeOH, or titanium tetraisopropoxide (Ti(O)2) in a solvent such as DCM or DCE containing an acid such as AcOH or TFA. i Optionally, the amine (10) may be present in the reaction as an acid salt such as a hydrogen chloride (HCl) salt, a hydrogen bromide (HBr) salt or a TFA salt, optionally in the presence of a tertiary base such as triethylamine (TEA) or N,N-diisopropylamine (DIPEA).
[0366] Amines of formula (10) may be of commercial origin or may be prepared by a variety of different methods known in the art and well known to the skilled artisan.
[0367] Ketones of formula (11) can be prepared by the reaction sequence shown in Scheme 1 below. Thus, an N-protected aminoketone (17) wherein the protecting group PG represents a suitable protecting group such as BOC or CBZ can be reacted under reducing conditions suitable to effect the formation of an N-protected aminoalcohol (18). Typically, such conditions can be reaction with a borohydride reducing agent such as sodium borohydride (NaBH4) in a solvent such as MeOH at a temperature of about -20°C to about 50°C, or reaction with lithium borohydride (LiBH4) in a solvent such as Et2O or THF, or reaction with an aluminum hydride reagent such as lithium aluminum hydride (LAH) in a solvent such as Et2O or THF. After formation, the N-protected aminoalcohol (18) can be deprotected to give the aminoalcohol (19). For example, when the protecting group PG is BOC, then suitable conditions to effect its removal can be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or Et2O, or reaction with TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ, then suitable conditions to effect its removal may be reaction with H2 in the presence of a palladium on carbon (Pd / C) catalyst in a solvent such as EtOH at a temperature of about 20°C to about 80°C. After formation, the amino alcohol (19) may be reacted with cyanogen bromide in a suitable solvent such as DCM, MeCN, Et2O or EtOH in the presence of a suitable base such as Et3N, NaHCO3, Na2CO3 or K2CO3, optionally in the presence of water at a temperature of about 0°C to about 50°C to form cyanamide (20). After formation, cyanamide (20) may be reacted with a suitable N-hydroxy reagent such as wherein R is in a suitable solvent such as EtOAc, Et2O, THF, 1,4-dioxane or EtOH or a mixture of the aforementioned solvents in the presence of a Lewis acid such as zinc chloride or zinc bromide at a temperature of about 0°C to about 25°C. 4 N-hydroxyamide (22) or the corresponding N-hydroxyamidine (23) as defined in any one of Embodiments 1.1 to 1.65 is reacted and then later heated in a suitable solvent such as EtOH in the presence of an aqueous acid, e.g., aqueous HCl, at a temperature of about 50°C to about 100°C to form alcohol (21). Alternatively, amino alcohol (19) may be reacted with wherein R in the presence of a suitable solvent such as THF, 1,4-dioxane, MeCN, EtOH, DMSO, DMF or NMP, optionally in the presence of a suitable base such as Et3N, DIPEA, K2CO3 or DBU, at a temperature suitable to promote the reaction, e.g., at a temperature of about 20°C to about 200°C, optionally using a sealed vessel at a reaction pressure greater than atmospheric pressure, optionally using conventional heating or microwave heating. 4Oxadiazoles (24) as defined in any of Embodiments 1.1 to 1.65 and where LG represents a suitable leaving group such as a halogen (e.g., fluorine, chloride or bromide) or a sulfonate (e.g., tosylate, mesylate or triflate) are directly reacted. Once formed, alcohols (21) can be oxidized to ketones (11) using a variety of reagents and conditions present in the art and well known to the skilled artisan, for example by using a chromium reagent such as pyridinium chlorochromate in a suitable solvent such as DCM at a temperature of about 0°C to about 25°C.
[0368]
[0369] In process variant (B), the ester (12) is reacted with an amine R 5 R 6 NH is reacted under conditions suitable for achieving the formation of an amide. Typically, such conditions are temperatures between about 0°C and about 110°C in a solvent such as toluene in combination with a reagent such as trimethylaluminum (Me3Al), optionally in the presence of a tertiary base such as TEA or DIPEA. It will be well known to the skilled person that there are a number of methods for achieving the formation of an amide from an ester (12) and an amine R 5 R 6 Other suitable conditions for NH amide formation are, for example, in the presence of isopropylmagnesium chloride ( i PrMgCl) in a suitable solvent, or by reacting ester (12) and amine R optionally in the presence of a suitable solvent, optionally in the presence of a suitable base such as TEA or DIPEA 5 R 6 NH is directly heated together with the reaction.
[0370] In process variant (C), the carboxylic acid (13) is reacted with an amine R 5 R 6 NH is reacted under conditions suitable to achieve the formation of an amide. The skilled person will be familiar with the existence of a number of techniques in the art for achieving the formation of an amide from a carboxylic acid (13) and an amine R 5 R 6There are many suitable conditions for amide formation from NH, for example, with amide coupling reagents such as diisopropylcarbodiimide (DIC), ethyl-(N',N'-dimethylamino)propylcarbodiimide hydrochloride (EDC), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), (1-cyano-2-ethoxy-2- The invention relates to a process for preparing an aqueous phase of the present invention and comprising the steps of: reacting a dimethylamino-morpholinyl-carbonium hexafluorophosphate (COMU) or 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphate-2,4,6-trioxide (T3P), optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of 1-hydroxybenzotriazole (HOBt), in a solvent such as DCM, THF or DMF, at a temperature between about 0°C and about 100°C.
[0371] Optionally, where R 1 Includes CONR 5 R 6 The compound of formula (1) can be prepared from a carboxylic acid (13) and an amine R 5 R 6 NH is prepared by the reaction sequence shown in Scheme 2 below:
[0372]
[0373] Thus, the carboxylic acid (13) can be reacted under conditions suitable to achieve the formation of the intermediate (25) wherein R 2 , R 4 , X 1 , X 2 , X 3 and X 4 is defined according to any one of Embodiments 1.1 to 1.65 and LG represents a suitable leaving group such as chloro (Cl), 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl). Typically, such conditions are reaction with a reagent such as oxalyl chloride or thionyl chloride (LG=Cl), 1,1'-carbonyldiimidazole (CDI) (LG=1-imidazole) or ethyl or isobutyl chloroformate (LG=RO(C=O)O), optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of a catalyst such as DMF, in a suitable solvent such as DCM, THF or DMF. After formation, intermediate (25) is reacted with an amine R 5 R 6 NH is reacted under conditions suitable to achieve formation of the amide (26) wherein R 2 , R 4 , R 5 , R6 , X 1 , X 2 , X 3 and X 4 is defined according to any one of Embodiments 1.1 to 1.65. Typically, such conditions are a reaction at a temperature between about 0°C and about 100°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA.
[0374] In process variant (D), an amine of formula (14) is reacted with a compound of formula (15) or a compound of formula (16) under suitable conditions to form an amine wherein R 1 Compounds of formula (1) including 5- or 6-membered rings containing N(C=O)OR or N(C=O)NR groups. Typically, such conditions are reactions at temperatures between about 0°C and about 100°C in solvents such as DCM, THF or DMF, optionally in the presence of a suitable base such as TEA, DIPEA or KCO.
[0375] In process variant (E), one compound of formula (1) can be converted into another compound of formula (1) by methods well known to the skilled person. Examples of synthetic procedures for converting one functional group into another functional group are described in standard texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th edition, Michael B. Smith, John Wiley, 2013, (ISBN: 978-0-470-46259-1), Organic Syntheses, online version, www.orgsyn.org, (ISSN 2333-3553) and Fiesers' Reagents for Organic Synthesis, Volumes 1-17, John Wiley, edited by Mary Fieser (ISBN: 0-471-58283-2).
[0376] In many of the reactions described above, it may be necessary to protect one or more groups to prevent reaction at undesirable locations of the molecule. Examples of protecting groups and examples of methods for protecting and deprotecting functional groups can be found in Greene's Protective Groups in Organic Synthesis, Fifth Edition, Editor: Peter GMWuts, John Wiley, 2014, (ISBN: 9781118057483).
[0377] The compounds prepared by the aforementioned methods can be isolated and purified by any of a variety of methods well known to those skilled in the art, and examples of such methods include recrystallization techniques and chromatographic techniques, such as column chromatography (eg flash chromatography), HPLC and SFC.
[0378] Pharmaceutical preparations
[0379] While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (eg, formulation).
[0380] Therefore, in another embodiment of the invention (Embodiment 4.1), there is provided a pharmaceutical composition comprising at least one compound of formula (1), (1a), (2), (3) or (4) as defined in any one of Embodiments 1.1 to 1.65, together with at least one pharmaceutically acceptable excipient.
[0381] In one embodiment (Embodiment 4.2), the composition is a tablet composition.
[0382] In another embodiment (Embodiment 4.3), the composition is a capsule composition.
[0383] Pharmaceutically acceptable excipients can be selected from, for example, carriers (e.g., solid carriers, liquid carriers, or semisolid carriers), adjuvants, diluents (e.g., solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and cosolvents), granulating agents, binders, glidants, coating agents, release controlling agents (e.g., polymers or waxes that slow or delay release), binding agents, disintegrants, buffers, lubricants, preservatives, antifungal and antibacterial agents, antioxidants, tonicity regulators, thickeners, flavoring agents, sweeteners, pigments, plasticizers, taste-masking agents, stabilizers, or any other excipients conventionally used in pharmaceutical compositions.
[0384] The term "pharmaceutically acceptable" as used herein means compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects (e.g., human subjects) without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio. Each excipient must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[0385] Pharmaceutical compositions comprising compounds of Formula (1), Formula (1a), Formula (2), Formula (3) or Formula (4) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
[0386] The pharmaceutical composition may be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, otic, rectal, intravaginal or transdermal administration.
[0387] Suitable pharmaceutical dosage forms for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers, or patches such as a buccal patch.
[0388] Tablet compositions may contain a unit dose of active compound together with an inert diluent or carrier, such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol, or mannitol; and / or a non-sugar derived diluent, such as sodium carbonate, calcium phosphate, calcium carbonate; or cellulose or its derivatives such as microcrystalline cellulose (MCC), methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, and starch such as corn starch. Tablets may also contain standard ingredients such as: binders and granulating agents, such as polyvinyl pyrrolidone; disintegrants (e.g., swellable cross-linked polymers such as cross-linked carboxymethyl cellulose); lubricants (e.g., stearates); preservatives (e.g., parabens); antioxidants (e.g., BHT); buffers (e.g., phosphate or citrate buffers); and effervescent agents such as citrate / bicarbonate mixtures. Such excipients are well known and need not be discussed in detail herein.
[0389] Tablets may be designed to release the drug upon contact with gastric fluid (immediate release tablets), or to release the drug in a controlled manner over an extended period of time or in a specific area of the GI tract (controlled release tablets).
[0390] The pharmaceutical composition generally comprises from about 1% (w / w) to about 95% (preferably % (w / w)) of active ingredient, and from 99% (w / w) to 5% (w / w) of a pharmaceutically acceptable excipient (e.g., as defined above) or a combination of such excipients. Preferably, the composition comprises from about 20% (w / w) to about 90% (w / w) of active ingredient and from 80% (w / w) to 10% of a pharmaceutically acceptable excipient or a combination of excipients. The pharmaceutical composition comprises from about 1% to about 95%, preferably from about 20% to about 90% of active ingredient. The pharmaceutical composition according to the present invention can, for example, be in the form of a unit dose, such as in the form of an ampoule, a vial, a suppository, a prefilled syringe, a dragee, a powder, a tablet or a capsule.
[0391] Tablets and capsules may contain, for example, 0%-20% disintegrants, 0%-5% lubricants, 0%-5% glidants, and / or 0%-99% (w / w) fillers or expanders (depending on the drug dose). They may also contain 0%-10% (w / w) polymer binders, 0%-5% (w / w) antioxidants, 0%-5% (w / w) pigments. In addition, slow-release tablets will typically contain 0%-99% (w / w) polymers that control (e.g., delay) release (depending on the dose). The film coating of a tablet or capsule typically contains 0%-10% (w / w) polymers, 0%-3% (w / w) pigments, and / or 0%-2% (w / w) plasticizers.
[0392] Parenteral formulations typically contain 0%-20% (w / w) buffer, 0%-50% (w / w) cosolvent and / or 0%-99% (w / w) water for injection (WFI) (depending on the dose and whether lyophilized). Formulations for intramuscular depots may also contain 0%-99% (w / w) oil.
[0393] The pharmaceutical preparations may be provided to the patient in a "patient pack" containing the entire course of treatment in a single package, usually a blister pack.
[0394] The compounds of formula (1), (1a), (2), (3) or (4) will typically be presented in unit dosage form, and will therefore typically contain enough compound to provide the desired level of biological activity. For example, the formulation may contain from 1 nanogram to 2 grams of active ingredient, for example from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, specific subranges of the compound are 0.1 milligram to 2 grams of active ingredient (more typically from 10 milligrams to 1 gram, for example 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (e.g. 1 microgram to 10 milligrams, for example 0.1 milligram to 2 milligrams of active ingredient).
[0395] For oral compositions, unit dosage forms may contain from 1 mg to 2 g, more typically 10 mg to 1 g, for example 50 mg to 1 g, for example 100 mg to 1 g, of active compound.
[0396] The active compound will be administered to a patient (eg, a human or animal patient) in need thereof in an amount sufficient to achieve the desired therapeutic effect (effective amount). The precise amount of compound administered can be determined by a supervising physician according to standard procedures. Example
[0397] The invention will now be illustrated without limiting the invention by reference to specific embodiments described in the following examples.
[0398] Example 1-1 to Example 18-2
[0399] The compounds of Example 1-1 to Example 18-2 shown in the following Table 1 have been prepared. Some of the NMR and LCMS properties of the compounds and the methods used to prepare them are set forth in Table 3. The starting materials and intermediates used in some of the Examples are listed in Table 2.
[0400]
[0401]
[0402]
[0403]
[0404]
[0405]
[0406]
[0407] General Procedure
[0408] Where preparative routes are not included, the relevant intermediates are commercially available. Commercial reagents were used without further purification. Room temperature (rt) refers to about 20°C-27°C. Data were recorded at 400 MHz on a Bruker or Jeol instrument. 1HNMR spectra. Chemical shift values are expressed in parts per million (ppm), i.e. (δ)-values. The following abbreviations are used for the multiplicity of NMR signals: s = singlet, br = broad, d = doublet, t = triplet, q = quartet, quint = quintet, td = triplet of doublet, tt = triplet of triplet, qd = quartet of doublet, ddd = doublet of doublet of doublet, ddt = doublet of doublet of triplet, m = multiplet. Coupling constants are listed as J values measured in Hz. NMR and mass spectrometry results are corrected to take into account background peaks. Chromatography refers to column chromatography performed using 60-120 mesh silica gel and under nitrogen pressure (flash chromatography). TLC used to monitor the reaction refers to TLC runs using a specified mobile phase and silica gel F254 from Merck as the stationary phase. Microwave-mediated reactions were performed in a Biotage Initiator or CEM Discover microwave reactor.
[0409] LCMS analysis
[0410] LCMS analysis of the compounds was performed under electrospray conditions using the instrumentation and methods given in the table below:
[0411] system Instrument Name LC Detector Quality detector 1 Waters 2695 Photodiode array ZQ-2000 Detector 2 Waters Acquity H Class Photodiode array SQ Detector 3 Shimadzu Nexera Photodiode array LCMS-2020 4 Agilent 1290 RRLC Photodiode array Agilent 6120 5 Hewlett Packard HP 1100 G1315A DAD Micromass ZQ
[0412]
[0413]
[0414] The LCMS data in the Experimental section and Tables 2 and 3 are given in the following format: (Instrument system, Method): mass ion, retention time, UV detection wavelength.
[0415] Compound purification
[0416] Final purification of compounds was performed by preparative reverse phase HPLC, chiral HPLC or chiral SFC using the instrumentation and methods detailed below, where data are given in the following format: Purification Technique: [Phase (column description, column length x internal diameter, particle size), solvent flow, gradient - given as % of mobile phase B in mobile phase A (over time), mobile phase (A), mobile phase (B)].
[0417] Preparative HPLC purification:
[0418] Shimadzu LC-20AP Binary System with SPD-20AUV Detector
[0419] Chiral HPLC purification:
[0420] Shimadzu LC-20AP Binary System with SPD-20A UV Detector
[0421] Chiral SFC purification:
[0422] Waters SFC 200
[0423] Sepiatec 100
[0424] Berger Multigram 2
[0425] Purification Method A
[0426] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL / min, gradient 10%-40% (in 23 min), 100% (in 2 min), 100%-10% (in 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0427] Purification method B
[0428] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 10%-33% (within 25 min), 100% (within 2 min), 10% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0429] Purification Method C
[0430] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 15 mL / min, gradient 37%-40% (in 23 min), 100% (in 2 min), 37% (in 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0431] Purification Method D
[0432] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 30%-40% (within 20 min), 100% (within 2 min), 100%-30% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0433] Purification Method E
[0434] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 5%-40% (within 20 min), 40% (within 3 min), 100% (within 2 min), 100%-5% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0435] Purification Method F
[0436] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 5 mL / min, gradient 15%-47% (within 15 min), 100% (within 1 min), 10% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0437] Purification Method G
[0438] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 5%-50% (within 17 min), 50%-70% (within 2 min), 100% (within 3 min), 100%-5% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0439] Purification Method H
[0440] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 16 mL / min, gradient 15%-42% (within 20 min), 100% (within 2 min), 100%-15% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0441] Purification Method I
[0442] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 16 mL / min, gradient 5%-30% (within 19 min), 100% (within 3 min), 100%-5% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0443] Purification method J
[0444] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 10 mL / min, gradient 0%-30% (within 45 min), 30%-30% (within 48 min), 100% (within 2 min), 100%-0% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0445] Purification Method K
[0446] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 5%-38% (within 25 min), 100% (within 2 min), 100%-5% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0447] Purification method L
[0448] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 16 mL / min, gradient 20%-30% (within 25 min), 30%-30% (within 5 min), 100% (within 3 min), 100%-20% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0449] Purification Method M
[0450] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL / min, gradient 15%-30% (within 30 min), 30%-30% (within 6 min), 100% (within 2 min), 100%-15% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0451] Purification Method N
[0452] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL / min, gradient 25%-35% (in 23 min), 100% (in 1 min), 100%-25% (in 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0453] Purification Method O
[0454] Chiral HPLC: [normal phase (CHIRALPAK AD-H, 250×21 mm, 5 μm), 18 mL / min, isocratic (A:B) 45:55 (within 45 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol:methanol (30:70)].
[0455] Purification Method P
[0456] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 13 mL / min, gradient 15%-20% (within 30 min), 20%-20% (within 6 min), 100% (within 1 min), 100%-15% (within 6 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0457] Purification Method Q
[0458] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 15 mL / min, gradient 5%-17% (within 32 min), 17%-17% (within 58 min), 100% (within 3 min), 100%-5% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0459] Purification Method R
[0460] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 20%-35% (within 25 min), 35%-35% (within 3 min), 100% (within 2 min), 100%-20% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0461] Purification method S
[0462] SFC: [(CHIRALCEL OX-H, 250×21 mm, 5 μm), 70 mL / min, isocratic (A:B) 70:30 (in 8.5 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in isopropanol:methanol (50:50)].
[0463] Purification method T
[0464] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 18%-30% (within 18 min), 100% (within 2 min), 100%-18% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0465] Purification Method U
[0466] Chiral HPLC: [normal phase (CHIRALCEL OX-H, 250×21 mm, 5 μm), 18 mL / min, isocratic (A:B) 90:10 (within 32 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol:acetonitrile (70:30)].
[0467] Purification Method V
[0468] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 15 mL / min, gradient 10%-25% (within 25 min), 25%-25% (within 7 min), 100% (within 2 min), 100%-10% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0469] Purification Method W
[0470] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL / min, gradient 25%-40% (in 15 min), 100% (in 3 min), 100%-25% (in 5 min), mobile phase (A): 0.1% ammonia in water, (B): 100% acetonitrile].
[0471] Purification MethodX
[0472] SFC: [(LUX A1, 250×21.2 mm, 5 μm), 50 mL / min, isocratic (A:B) 65:35, mobile phase (A): 100% liquid CO2, (B): 0.1% ammonia in methanol].
[0473] Purification Method Y
[0474] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 8%-20% (within 23 min), 20%-20% (within 2 min), 100% (within 2 min), 100%-8% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0475] Purification method Z
[0476] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 75 mL / min, isocratic (A:B) 82:18 (within 20 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in methanol].
[0477] Purification Method AA
[0478] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 8%-23% (within 17 min), 23%-23% (within 2 min), 100% (within 2 min), 100%-8% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0479] Purification Method AB
[0480] Preparative HPLC: [reverse phase (YMC ACTUS TRIART C-18, 250×20 mm, 5 μm), 15 mL / min, gradient 15%-30% (within 28 min), 100% (within 2 min), 100%-15% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0481] Purification Method AC
[0482] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 75 mL / min, isocratic (A:B) 75:25 (within 18 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in methanol].
[0483] Purification Method AD
[0484] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×50 mm, 5 μm), 90 mL / min, gradient 5%-35% (within 20 min), 100% (within 2 min), 100%-5% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0485] Purification Method AE
[0486] Chiral HPLC: [normal phase (CHIRALPAK AD-H, 250×21 mm, 5 μm), 18 mL / min, isocratic (A:B) 70:30 (within 35 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol:methanol (50:50)].
[0487] Purification Method AF
[0488] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 13 mL / min, gradient 15%-30% (within 30 min), 30%-30% (within 10 min), 100% (within 2 min), 100%-15% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0489] Purification Method AG
[0490] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 80 mL / min, isocratic (A:B) 75:25 (within 13 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in isopropanol:methanol (50:50)].
[0491] Purification Method AH
[0492] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×50 mm, 5 μm), 80 mL / min, gradient 5%-18% (within 50 min), 18%-18% (within 10 min), 100% (within 3 min), 100%-5% (within 7 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0493] Purification Method AI
[0494] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 80 mL / min, isocratic (A:B) 70:30 (within 20 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in methanol].
[0495] Purification Method AJ
[0496] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 0%-27% (within 28 min), 27%-27% (within 6 min), 100% (within 4 min), 100%-0% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0497] Purification Method AK
[0498] Chiral HPLC: [normal phase (CHIRALPAK AD-H, 250×21 mm, 5 μm), 18 mL / min, isocratic (A:B) 90:10 (within 27 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol].
[0499] Purification Method AL
[0500] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 15%-35% (within 20 min), 35%-35% (within 3 min), 100% (within 2 min), 100%-15% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0501] Purification Method AM
[0502] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 80 mL / min, isocratic (A:B) 65:35 (within 16.5 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in methanol].
[0503] Purification Method AN
[0504] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 15 mL / min, gradient 10%-30% (within 20 min), 30%-30% (within 5 min), 100% (within 2 min), 100%-10% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0505] Purification Method AO
[0506] Chiral HPLC: [normal phase (CHIRALPAK AD-H, 250×21 mm, 5 μm), 18 mL / min, isocratic (A:B) 85:15 (within 30 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol].
[0507] Purification Method AP
[0508] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 16 mL / min, gradient 10%-32% (within 18 min), 100% (within 2 min), 100%-10% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0509] Purification method AQ
[0510] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 13 mL / min, gradient 20%-25% (within 17 min), 25%-25% (within 3 min), 100% (within 2 min), 100%-20% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0511] Purification Method AR
[0512] Chiral HPLC: [normal phase (CHIRALCEL OX-H, 250×21 mm, 5 μm), 18 mL / min, isocratic (A:B) 78:22 (within 37 min), mobile phase (A): 0.1% diethylamine in hexane, (B): 0.1% diethylamine in isopropanol:methanol (50:50)].
[0513] Purification method AS
[0514] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL / min, gradient 25%-38% (in 16 min), 100% (in 2 min), 100%-25% (in 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0515] Purification Method AT
[0516] Preparative HPLC: [reverse phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL / min, gradient 5%-35% (in 20 min), 100% (in 4 min), 100%-5% (in 4 min), mobile phase (A): 0.1% ammonia in water, (B): 100% acetonitrile].
[0517] Purification Method AU
[0518] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 5%-28% (within 18 min), 28%-28% (within 2 min), 100% (within 2 min), 100%-5% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0519] Purification Method AV
[0520] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 10%-20% (within 25 min), 20%-20% (within 8 min), 100% (within 2 min), 100%-10% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0521] Purification Method AW
[0522] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL / min, gradient 15%-20% (within 22 min), 20%-20% (within 5 min), 100% (within 2 min), 100%-15% (within 6 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0523] Purification Method AX
[0524] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 10 mL / min, gradient 5%-55% (within 18 min), 55%-55% (within 6 min), 100% (within 2 min), 100%-5% (within 6 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0525] Purification method AY
[0526] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 15 mL / min, gradient 20%-45% (within 22 min), 100% (within 2 min), 100%-20% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0527] Purification methods A-Z
[0528] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 16 mL / min, gradient 30%-39% (within 14 min), 100% (within 2 min), 100%-30% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0529] Purification method BA
[0530] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 80 mL / min, isocratic (A:B) 85:15 (within 7 min), mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in methanol].
[0531] Purification method BB
[0532] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 13 mL / min, gradient 25%-35% (within 28 min), 35%-35% (within 2 min), 100% (within 2 min), 100%-25% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0533] Purification Method BC
[0534] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 13 mL / min, gradient 25%-40% (within 30 min), 40%-40% (within 2 min), 100% (within 2 min), 100%-25% (within 6 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0535] Purification Method BD
[0536] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 14 mL / min, gradient 20%-50% (within 20 min), 50%-50% (within 5 min), 100% (within 2 min), 100%-20% (within 6 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0537] Purification method BE
[0538] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 12 mL / min, gradient 5%-50% (within 23 min), 50%-50% (within 5 min), 100% (within 2 min), 100%-5% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0539] Purification Method BF
[0540] Preparative HPLC: [reverse phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 13 mL / min, gradient 5%-55% (within 22 min), 55%-55% (within 6 min), 100% (within 2 min), 100%-5% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0541] Purification Method BG
[0542] Preparative HPLC: [reverse phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 14 mL / min, gradient 25%-52% (within 25 min), 52%-52% (within 9 min), 100% (within 2 min), 100%-25% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate in water + 0.1% ammonia in water, (B): 100% acetonitrile].
[0543] abbreviation
[0544] AcOH = acetic acid
[0545] aq.=water
[0546] DCM = dichloromethane
[0547] DIPEA = diisopropylethylamine
[0548] DMF = dimethylformamide
[0549] DMSO = dimethyl sulfoxide
[0550] ES(I)=Electrospray ionization
[0551] Et2O = diethyl ether
[0552] EtOAc = Ethyl acetate
[0553] EtOH = ethanol
[0554] h = hours
[0555] H2O=water
[0556] HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
[0557] HCl = Hydrogen chloride, hydrochloric acid
[0558] HPLC = High Performance Liquid Chromatography
[0559] LC = Liquid Chromatography
[0560] MeCN = acetonitrile
[0561] MeOH = methanol
[0562] min(s)=minutes
[0563] MS = mass spectrometry
[0564] nm = nanometer
[0565] NMR = Nuclear Magnetic Resonance
[0566] sat.=saturated
[0567] SFC = Supercritical Fluid Chromatography
[0568] STAB = Sodium triacetoxyborohydride
[0569] TFA = trifluoroacetic acid
[0570] THF = Tetrahydrofuran
[0571] TLC = Thin Layer Chromatography
[0572] The prefixes n-, s-, i-, t-, and tert- have their usual meanings: normal, secondary, iso, and tertiary.
[0573] Synthesis of intermediates:
[0574] Route 1
[0575] Typical procedures for the preparation of ketones, as exemplified by the preparation of intermediate 3—2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]heptan-6-one
[0576]
[0577] 6-Oxo-2-azaspiro [3.3] heptane-2-carboxylic acid tert-butyl ester (intermediate 1) (500mg, 2.37mmol) was dissolved in MeOH (10mL), and the resulting solution was cooled to 0°C. Sodium borohydride (270mg, 7.10mmol) was added in batches, and the resulting reaction mixture was stirred at 25°C for 2h. The solvent was removed in vacuo, and the residue was distributed between H2O (80mL) and EtOAc (60mL). The aqueous layer was further extracted with EtOAc (2×60mL), and the organic layers were combined, dried (Na2SO4), and the solvent was removed in vacuo. The residue was ground with pentane to give tert-butyl 6-hydroxy-2-azaspiro [3.3] heptane-2-carboxylate (500mg, 99%) as a solid.
[0578] LCMS (System 2, Method E): m / z 214 (M+H) + (ESI+ve), at 1.54min, 202nm.
[0579] Tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate (500 mg, 2.34 mmol) was dissolved in DCM (10 mL) and the resulting solution was cooled to 0° C. Trifluoroacetic acid (1 mL) was added dropwise and the resulting reaction mixture was stirred at 25° C. for 6 h. The solvent was removed in vacuo and the residue was triturated with pentane (3×1 mL) to give 2-azaspiro[3.3]heptan-6-ol trifluoroacetate (260 mg, 98%) as a gum.
[0580] LCMS (System 2, Method E): m / z 114 (M+H) + (ESI+ve), at 0.22min, 202nm.
[0581] 2-Azaspiro [3.3] heptane-6-ol trifluoroacetate (250 mg, 2.21 mmol) was dissolved in DCM (10 mL), treated with saturated aqueous NaHCO (1 mL), and cooled to 0 ° C for 10 min. Cyanogen bromide (255 mg, 2.43 mmol) was added in batches, and the resulting reaction mixture was stirred at 25 ° C for 5 h. The solvent was removed in vacuo, and the residue was alkalized with a saturated NaHCO aqueous solution. The precipitated solid was removed by filtration and washed 5 to 6 times with DCM. The combined filtrate and washings were then dried (Na2SO4), the solvent was removed in vacuo, and the crude product was purified by grinding with pentane to give 6-hydroxy-2-azaspiro [3.3] heptane-2-carbonitrile (230 mg, 75%) as a jelly.
[0582] LCMS (System 2, Method E): m / z 139 (M+H) + (ESI+ve), at 0.76min, 202nm.
[0583] 6-Hydroxy-2-azaspiro[3.3]heptane-2-carbonitrile (180 mg, 1.30 mmol) was dissolved in a mixture of EtOAc:Et2O (5:1) (5 mL), and N-hydroxyacetamide (intermediate 2) (125 mg, 1.69 mmol) was added. The resulting mixture was stirred at 25 °C for 5 min, and then a solution of ZnCl2 in diethyl ether (1 M, 1 mL, 1 mmol) was added dropwise. The reaction mixture was stirred at 25 °C for 20 min, during which a white precipitate was formed. The reaction mixture was diluted with Et2O (3 × 10 mL), and the solvent was decanted each time. The remaining solid was dissolved in EtOH (3 mL), treated with aqueous HCl (4 M, 2 mL), and heated at reflux for 6 h. The solvent was removed in vacuo, and the residue was alkalized with aqueous NaHCO3, and then distributed between H2O (80 mL) and DCM (60 mL). The aqueous layer was further extracted with DCM (2×60 mL), and the combined organic layers were dried (Na 2 SO 4 ), and the solvent was removed in vacuo. The residue was purified by trituration with pentane to give 2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]heptan-6-ol (60 mg, 24%) as a gum.
[0584] LCMS (System 2, Method E): m / z 196 (M+H) + (ESI+ve), at 1.34min, 202nm.
[0585] 2-(3-methyl-1,2,4-oxadiazole-5-yl)-2-azaspiro[3.3]heptan-6-ol (80 mg, 0.41 mmol) was dissolved in DCM (5 mL), and the solution was cooled to 0 ° C. Chlorochromic acid pyridinium salt (132 mg, 0.62 mmol) was added in batches, and the resulting reaction mixture was stirred at 25 ° C for 3 h. The solvent was then removed in vacuo, and the residue was alkalized with NaHCO3 solution and distributed between H2O (60 mL) and EtOAc (45 mL). The water layer was further extracted with EtOAc (2×45 mL), and the combined organic layer was dried (Na2SO4), and the solvent was removed in vacuo. The residue was triturated with pentane to give 2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]heptan-6-one (Intermediate 3) (60 mg, 76%) as a gum.
[0586] The data for Intermediate 3 are in Table 2.
[0587] Route 2
[0588] A typical procedure for the preparation of alcohols, as exemplified by the preparation of the intermediate 6-6-azaspiro[3.4]octan-2-ol hydrochloride
[0589]
[0590] tert-Butyl 2-oxo-6-azaspiro[3.4]octane-6-carboxylate (Intermediate 5) (10 g, 44.3 mmol) was dissolved in MeOH (1000 mL) and the resulting solution was cooled to 0°C. Sodium borohydride (2.0 g, 53.2 mmol) was added in portions and the resulting reaction mixture was stirred at 25°C for 1 h. The solvent was removed in vacuo and the residue was partitioned between H2O (250 mL) and EtOAc (250 mL). The aqueous layer was further extracted with EtOAc (2×150 mL) and the organic layers were combined, dried (Na2SO4), and the solvent was removed in vacuo to give tert-butyl 2-hydroxy-6-azaspiro[3.4]octane-6-carboxylate (9.2 g, 91%) as a gum.
[0591] LCMS (System 3, Method F): m / z 228 (M+H) + (ESI+ve), at 3.09min, 202nm.
[0592] Tert-butyl 2-hydroxy-6-azaspiro[3.4]octane-6-carboxylate (9 g, 39.6 mmol) was slowly dissolved in a solution of HCl in 1,4-dioxane (4 M, 90 mL) and the resulting reaction mixture was stirred at 25° C. for 16 h. The solvent was removed in vacuo and the residue was purified by trituration with diethyl ether (3×50 mL) to give 6-azaspiro[3.4]octan-2-ol hydrochloride (Intermediate 6) (7 g, 90%) as a gum.
[0593] The data for Intermediate 6 are in Table 2.
[0594] Route 3
[0595] Typical procedures for the preparation of alcohols, as exemplified by the preparation of intermediate 27—2-azabicyclo[2.2.2]octan-5-ol hydrochloride
[0596]
[0597] 5-Oxo-2-azabicyclo [2.2.2] octane-2-carboxylic acid tert-butyl ester (intermediate 26) (500 mg, 2.2 mmol) was dissolved in THF (10 mL), and the solution was cooled to -20 ° C under a nitrogen atmosphere. A lithium aluminum hydride solution (1M, 3.3 mL, 3.3 mmol) in THF was added at -20 ° C, and the resulting mixture was stirred at 0 ° C for 2 h. The reaction mixture was partitioned between cold H2O (25 mL) and EtOAc (15 mL), and the aqueous layer was further extracted with EtOAc (2×15 mL). The combined organic layers were dried (Na2SO4), and the solvent was removed in vacuo to give 5-hydroxy-2-azabicyclo [2.2.2] octane-2-carboxylic acid tert-butyl ester (500 mg, 99%) as a gum.
[0598] LCMS (System 2, Method E): m / z 172 (M+H-56) + (ESI+ve), at 1.60min, 202nm.
[0599] Tert-butyl 5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate (500 mg, 2.2 mmol) was dissolved in a solution of HCl in 1,4-dioxane (4M, 10 mL) at 0° C. and then stirred at room temperature for 2 h. The solvent was removed in vacuo and the residue was triturated with n-pentane (2×10 mL) to give 2-azabicyclo[2.2.2]octan-5-ol hydrochloride (Intermediate 27) (280 mg, 100%) as a solid.
[0600] The data for intermediate 27 are in Table 2.
[0601] Route 4
[0602] Typical procedures for the preparation of alcohols, as exemplified by the preparation of intermediate 30 — 9-azabicyclo[3.3.1]nonan-3-ol trifluoroacetate
[0603]
[0604] A solution of lithium aluminum hydride in THF (1M, 37.6 mL, 37.6 mmol) was added dropwise at 0°C to a solution of tert-butyl 3-oxo-9-azabicyclo [3.3.1] nonane-9-carboxylate (intermediate 29) (6 g, 25.1 mmol) in THF (60 mL), and the reaction mixture was stirred at 0°C for 4 h. The reaction was then quenched by adding ice-cold water (20 mL), and the mixture was extracted with ethyl acetate (2×50 mL). The organic layers were combined, dried (Na2SO4), and the solvent was removed in vacuo to give tert-butyl 3-hydroxy-9-azabicyclo [3.3.1] nonane-9-carboxylate (6 g, 99%) as a solid. The product was used crude in the next step without further purification or characterization.
[0605] tert-Butyl 3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate (6 g, 24.1 mmol) was dissolved in DCM (30 mL) and the resulting solution was cooled to 0°C. TFA (15 mL) was added and the mixture was stirred at room temperature for 4 h. The solvent was removed in vacuo and the residue was triturated with toluene (2 x 15 mL) to give 9-azabicyclo[3.3.1]nonan-3-ol trifluoroacetate (Intermediate 30) (8.5 g, 100%) as a gum.
[0606] The data for Intermediate 30 are in Table 2.
[0607] Route 5
[0608] Typical procedures for the preparation of amines, as exemplified by the preparation of intermediate 47 - [(2R,4R)-4-fluoro-1-(piperidin-4-yl)pyrrolidin-2-yl]methanol trifluoroacetate
[0609]
[0610] Methyl (2R,4R)-4-fluoropyrrolidine-2-carboxylate hydrochloride (Intermediate 45) (11.3 g, 61.7 mmol) was dissolved in methanol (280 mL) and tert-butyl 4-oxopiperidine-1-carboxylate (Intermediate 46) (12.2 g, 61.7 mmol), triethylamine (13 mL, 92.6 mmol) and 10% palladium on carbon catalyst (-50% wet with H2O, 6 g) were added. The reaction mixture was stirred under hydrogen at one atmosphere at 25 °C for 18 h, then filtered through celite and the filtrate was concentrated in vacuo. The resulting crude product was triturated with pentane to give tert-butyl 4-[(2R,4R)-4-fluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidine-1-carboxylate (18 g, 89%) as a solid.
[0611] LCMS (System 1, Method D): m / z 331 (M+H) + (ESI+ve), at 4.23min, 210nm.
[0612] Tert-butyl 4-[(2R,4R)-4-fluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidine-1-carboxylate (18 g, 54.5 mmol) was dissolved in THF (200 mL), and the resulting solution was cooled to 0 ° C. A solution of lithium borohydride (3M, 54 mL, 164 mmol) in THF was then added dropwise, and the mixture was stirred at 25 ° C for 17 h. The solvent was removed in vacuo, and the residue was alkalized with saturated NaHCO3 solution and distributed between H2O (600 mL) and DCM (400 mL). The aqueous layer was further extracted with EtOAc (2×400 mL), and all organic layers were then combined, dried (Na2SO4), and the solvent was removed in vacuo. The residue was purified by trituration with pentane (3 x 10 mL) to give tert-butyl 4-[(2R,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidine-1-carboxylate (14.5 g, 88%) as a gum.
[0613] LCMS (System 1, Method D): m / z 303 (M+H) + (ESI+ve), at 3.57min, 210nm.
[0614] Tert-butyl 4-[(2R,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidine-1-carboxylate (14.5 g, 0.42 mmol) was dissolved in DCM (100 mL) and the resulting solution was cooled to 0° C. Trifluoroacetic acid (30 mL) was added dropwise and the reaction mixture was stirred at 25° C. for 8 h. The solvent was removed in vacuo and the residue was purified by trituration with pentane (3×10 mL) to give [(2R,4R)-4-fluoro-1-(piperidin-4-yl)pyrrolidin-2-yl]methanol trifluoroacetate (Intermediate 47) (9.60 g, 100%) as a colorless gum.
[0615] The data for intermediate 47 are in Table 2.
[0616] Route 6
[0617] Typical procedures for the preparation of amines, as exemplified by the preparation of Intermediate 51 - 4-[2-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl]piperidine trifluoroacetate
[0618]
[0619] 1-Methyl-4-(pyrrolidin-2-yl)-1H-pyrazole (intermediate 50) (0.25g, 1.66mmol), tert-butyl 4-oxopiperidine-1-carboxylate (intermediate 46) (0.32g, 1.66mmoL), ZnCl2 solution (1M, 0.083mL, 0.083mmol) and triethylamine (0.72mL, 4.97mmol) in diethyl ether were dissolved in MeOH (10mL), and the resulting mixture was stirred at 70°C for 4h. The mixture was then cooled to 0°C, and NaBH3CN (0.21g, 3.31mmoL) was added in batches. The reaction mixture was stirred at room temperature for 16h, and the solvent was then removed in vacuo. The residue was distributed between H2O (50mL) and EtOAc (100mL), and the aqueous layer was further extracted with EtOAc (2×100mL). The combined organic layers were dried (Na2SO4) and the solvent was removed in vacuo to give the crude product which was purified by column chromatography using alumina and MeOH / DCM as solvent to give tert-butyl 4-(2-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl)piperidine-1-carboxylate (0.33 g, 59%) as a gum.
[0620] LCMS (System 3, Method F): m / z 335 (M+H) + (ESI+ve), at 3.23min, 215nm.
[0621] To a stirred solution of tert-butyl 4-(2-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl)piperidine-1-carboxylate (0.30 g, 0.90 mmol) in DCM (3 mL) was added TFA (3 mL) dropwise at 0° C. and the resulting mixture was stirred at room temperature for 3 h. The solvent was evaporated in vacuo and the residue was co-evaporated from toluene (3×5 mL) to give 4-[2-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl]piperidine trifluoroacetate (Intermediate 51) (0.20 g, 95%) as a gum.
[0622] The data for intermediate 51 are in Table 2.
[0623] Route 7
[0624] Typical procedures for the preparation of ketones, as exemplified by the preparation of intermediate 60 - 8-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-one
[0625]
[0626] Trifluoroacetic acid (25 mL) was added dropwise to a solution of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (Intermediate 17) (10 g, 44.4 mmol) in DCM (100 mL) at 0° C. The resulting mixture was stirred at room temperature for 2 h, then the solvent was evaporated under reduced pressure and the residue was triturated with toluene (3×15 mL) to give crude 8-azabicyclo[3.2.1]octan-3-one trifluoroacetate (16 g, 100%), which was carried forward to the next reaction without further purification.
[0627] LCMS (System 4, Method B): m / z 126 (M+H) + (ESI+ve), at 2.20min, 214nm.
[0628] Under vigorous stirring, a solution of 8-azabicyclo[3.2.1]octan-3-one trifluoroacetate (16 g, 0.067 mol) in DCM (150 mL) was added dropwise to a solution of sodium bicarbonate (26 g, 0.32 mol) in water (100 mL). A solution of cyanogen bromide (16.3 g, 0.153 mol) in DCM (25 mL) was then added at 0 ° C, the ice bath was removed, and the resulting reaction mixture was stirred at room temperature for 16 h. Solid sodium carbonate was added until the pH was adjusted to 7, and the mixture was then extracted with DCM (3×25 mL). The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (normal phase, silica gel 60-120 mesh, 0% to 3% MeOH in DCM) to provide 3-oxo-8-azabicyclo[3.2.1]octane-8-carbonitrile (6.5 g, 65%).
[0629] LCMS (System 4, Method B): m / z 151 (M+H) + (ESI+ve), at 4.13min, 202nm.
[0630] 3-Oxo-8-azabicyclo[3.2.1]octane-8-carbonitrile (1 g, 6.65 mmol) and 2,2,2-trifluoro-N-hydroxytacetimidamide (Intermediate 59) (1 g, 7.99 mmol) were dissolved in ethanol (50 mL), a ZnCl2 solution in diethyl ether (1 M, 7.99 mL, 7.99 mmol) was added, and the resulting mixture was stirred at room temperature for 16 h. Aqueous HCl (4 M, 6 mL) was then added, and the mixture was heated at reflux at 90 °C overnight. Saturated sodium bicarbonate solution (50 mL) was added, and the mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4, concentrated under reduced pressure, and the residue was purified by column chromatography (normal phase, silica gel 60-120 mesh, 0% to 7% EtOAC in hexanes) to give 8-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 60) (517 mg, 30%).
[0631] The data for intermediate 60 are in Table 2.
[0632] Route 8
[0633] Typical procedures for the preparation of amines, as exemplified by the preparation of intermediate 62—(1R,5S,6r)-N-(-methylcyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide hydrochloride
[0634]
[0635] (1R, 5S, 6r) -3- azabicyclo [3.1.0] hexane -6- ethyl carboxylate (intermediate 9) (2.0 g, 8.16 mmol) was dissolved in DCM (25 mL) and triethylamine (3.45 mL, 24.5 mmol) was added. The mixture was cooled to 0 ° C, stirred for 20 min, and di-tert-butyl dicarbonate (2.65 g, 12.2 mmol) was added. The resulting reaction mixture was then stirred at 25 ° C for 18 h. The solvent was removed in vacuo, and the residue was distributed between H2O (80 mL) and ethyl acetate (60 mL). The water layer was further extracted with ethyl acetate (2 × 60 mL), the combined organic layer was dried (Na2SO4), and the solvent was removed in vacuo. The residue was purified by column chromatography (normal phase activated Al2O3, 0% to 40% ethyl acetate in hexanes) to give 3-(tert-butyl)6-ethyl(1R,5S,6r)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate (1.70 g, 82%) as a liquid.
[0636] LCMS (System 3, Method F): m / z 241 (M-15+H) + (ESI+ve), at 4.06min, 202nm.
[0637] 1-Methylcyclobutane-1-amine hydrochloride (intermediate 61) (948 mg, 7.84 mmol) was suspended in toluene (10 mL) and triethylamine (1.70 mL, 11.8 mmol) was added. The mixture was cooled to -10 °C, trimethylaluminum solution (2M, 5.9 mL, 11.8 mmol) in toluene was added dropwise, and stirring was continued for 20 min. 3-(tert-butyl) 6-ethyl (1R, 5S, 6r) -3-azabicyclo [3.1.0] hexane-3,6-dicarboxylate (1.0 g, 3.92 mmol) was added at -10 °C, and the reaction mixture was then stirred at 70 °C for 40 h. The solvent was removed in vacuo, and the residue was distributed between H2O (80 mL) and ethyl acetate (60 mL). The water layer was further extracted with ethyl acetate (2 × 80 mL), and the combined organic layer was dried (Na2SO4), and the solvent was removed in vacuo. The residue was purified by column chromatography (normal phase activated Al2O3, 0% to 60% ethyl acetate in hexanes) to give (1R,5S,6r)-tert-butyl 6-((1-methylcyclobutyl)carbamoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (560 mg, 49%) as a solid.
[0638] LCMS (System 3, Method F): m / z 293 (MH)-(ESI-ve), at 3.80 min, 202 nm.
[0639] Tert-butyl (1R,5S,6r)-6-((1-methylcyclobutyl)carbamoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (550 mg, 1.87 mmol) was dissolved in 1,4-dioxane (6 mL), and the solution was cooled to 0°C. A solution of HCl in 1,4-dioxane (4M, 10 mL) was added, and the reaction mixture was stirred at 25°C for 5 h. The solvent was removed in vacuo, and the residue was purified by trituration with pentane (3 x 3 mL) to give (1R,5S,6r)-N-(1-methylcyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide hydrochloride (Intermediate 62) (408 mg, 95%) as a solid.
[0640] The data for intermediate 62 are in Table 2.
[0641] Route 9
[0642] Typical procedures for the preparation of amines, as exemplified by the preparation of intermediate 68 - N-((1-methylcyclobutyl)methyl)piperidine-4-carboxamide trifluoroacetate
[0643]
[0644] 1-(tert-butyl) 4-ethylpiperidine-1,4-dicarboxylate (intermediate 64) (700 mg, 0.0027 mole) and (1-methylcyclobutyl)methylamine (intermediate 65) (434 mg, 0.0032 mole) were dissolved in toluene (3.0 mL), and triethylamine (1.13 mL, 0.008 mole) was added, followed by a trimethylaluminum solution (2M, 5.44 mL, 0.0108 mole) in toluene added dropwise at -20 ° C. The mixture was stirred at -20 ° C for 30 min, and then heated at 80 ° C for 48 hours. The reaction mixture was concentrated under reduced pressure, and the residue was distributed between cold H2O (200 mL) and DCM (100 mL). The water layer was further extracted with DCM (2×100 mL), and the combined organic layer was dried (Na2SO4), and the solvent was removed in vacuo. The crude product was purified by column chromatography (normal phase, 100-120 mesh silica gel, 0% to 39% ethyl acetate in hexanes) to give tert-butyl 4-(((1-methylcyclobutyl)methyl)carbamoyl)piperidine-1-carboxylate (320 mg, 38%) as a solid.
[0645] LCMS (System 2, Method H): m / z 311 (M+H) + (ESI+ve), at 1.71min, 202nm.
[0646] A solution of tert-butyl 4-(((1-methylcyclobutyl)methyl)carbamoyl)piperidine-1-carboxylate (320 mg, 0.00103 mol) in DCM (2 mL) was cooled to 0 °C and TFA (1 mL) was added dropwise, then the resulting reaction mixture was stirred at RT for 2 h. The solvent was removed in vacuo, and the residue was purified by trituration with toluene (3 x 5 mL) to give crude N-((1-methylcyclobutyl)methyl)piperidine-4-carboxamide trifluoroacetate (intermediate 66) (410 mg, 100%), which was used without further purification.
[0647] The data for intermediate 66 are in Table 2.
[0648] General synthesis procedure:
[0649] Route A
[0650] Typical procedures for preparing amines, as exemplified by the preparation of Example 1-1 - 2-(3-methyl-1,2,4-oxadiazol-5-yl)-6-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-2-azaspiro[3.3]heptane
[0651]
[0652] 4-(1H-pyrazol-1-yl)piperidine (Intermediate 4) (47 mg, 0.31 mmol), 2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-azaspiro[3.3]heptan-6-one (Intermediate 3) (60 mg, 0.31 mmol), triethylamine (0.1 mL, 0.93 mmol) and ZnCl2 (4 mg, 0.03 mmol) were dissolved in MeOH (10 mL) and the resulting mixture was stirred at 65 °C for 8 h. The mixture was then cooled to 0 °C and NaBH3CN (58 mg, 0.93 mmol) was added portionwise and the resulting reaction mixture was stirred at 25 °C for 16 h. The solvent was removed in vacuo, the residue was partitioned between H2O (50 mL) and EtOAc (40 mL), and the aqueous layer was further extracted with EtOAc (2×40 mL). The combined organic layers were dried (Na2SO4), the solvent was removed in vacuo, and the residue was purified using purification method A to give 2-(3-methyl-1,2,4-oxadiazol-5-yl)-6-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-2-azaspiro[3.3]heptane (Example 1-1) as a solid (17 mg, 17%).
[0653] The data of Example 1-1 is in Table 3.
[0654] Route B
[0655] Typical procedures for preparing amines, as exemplified by the preparation of Example 6-5 - N-(1-methylcyclobutyl)-1-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]piperidine-4-carboxamide
[0656]
[0657] Triethylamine (0.12 ml, 0.86 mmol) was added dropwise to a solution of 1-methylcyclobutane-1-amine (intermediate 25) (27 mg, 0.3 mmol) in toluene (10 mL), and the mixture was stirred at room temperature for 15 min. 1-[8-(3-methyl-1,2,4-oxadiazole-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]piperidine-4-carboxylic acid ethyl ester (intermediate 24) (100 mg, 0.29 mmol) was added, and the reaction mixture was stirred at room temperature for 15 min, and then cooled to 0 ° C. A solution of trimethylaluminum in toluene (2M, 0.43 mL, 0.86 mmol) was added at 0 ° C, and the reaction mixture was then stirred at 80 ° C for 16 h. The mixture was partitioned between H2O (10 mL) and ethyl acetate (20 mL), and the aqueous layer was further extracted with ethyl acetate (2×20 mL). The combined organic layers were dried (Na2SO4) and the solvent was removed in vacuo to give the crude product, which was purified by Purification Method L to give N-(1-methylcyclobutyl)-1-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]piperidine-4-carboxamide, Example 6-5 Isomer 1 as a gum (40 mg, 24%) and N-(1-methylcyclobutyl)-1-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl]piperidine-4-carboxamide, Example 6-5 Isomer 2 as a solid (5 mg, 3%).
[0658] The data for Example 6-5 Isomer 2 are in Table 3.
[0659] Route C
[0660] Typical procedures for the preparation of amines, as exemplified by the preparation of Example 10-12 - (2S)-N-methyl-2-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidine-1-carboxamide
[0661]
[0662] To a stirred solution of (2S)-tert-butyl 2-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidine-1-carboxylate (Intermediate 54) (260 mg, 0.60 mmol) in DCM (3 mL) was added TFA (3 mL) dropwise at 0° C. The reaction mixture was stirred at room temperature for 3 h, then the solvent was evaporated in vacuo and the residue was co-evaporated from toluene (3×5 mL) to give 1-(3-methyl-1,2,4-oxadiazol-5-yl)-4-{4-[(2S)-pyrrolidin-2-yl]piperidin-1-yl}azepane trifluoroacetate (190 mg, 95%) as a gum.
[0663] LCMS (System 3, Method F): m / z 334 (M+H) + (ESI+ve), at 1.95min, 225nm.
[0664] To a stirred solution of 1-(3-methyl-1,2,4-oxadiazol-5-yl)-4-{4-[(2S)-pyrrolidin-2-yl]piperidin-1-yl}azepane trifluoroacetate (300 mg, 1.29 mmol) in DMF (3 mL) was added KCO (533 mg, 3.86 mmol), and the resulting mixture was stirred at room temperature for 1 h. Methylcarbamoyl chloride (Intermediate 55) (240 mg, 2.58 mmol) was added, and the reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was then diluted with ice-cold water (10 mL) and extracted with EtOAc (20 mL). The aqueous layer was further extracted with EtOAc (2×10 mL), then all organic layers were combined, dried (Na 2 SO 4 ) and evaporated under reduced pressure to give the crude product, which was purified by Purification Method AQ followed by Purification Method AR to give (2S)-N-methyl-2-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidine-1-carboxamide, Example 10-12 Isomer 1 as a gum (11 mg, 2%) and (2S)-N-methyl-2-{1-[1-(3-methyl-1,2,4-oxadiazol-5-yl)azepan-4-yl]piperidin-4-yl}pyrrolidine-1-carboxamide, Example 10-12 Isomer 2 as a gum (10 mg, 2%).
[0665] The data for Examples 10-12 Isomer 1 and Examples 10-12 Isomer 2 are in Table 3.
[0666] Table 2 - Starting Materials and Intermediates
[0667]
[0668]
[0669]
[0670]
[0671]
[0672]
[0673]
[0674]
[0675]
[0676]
[0677]
[0678]
[0679]
[0680]
[0681]
[0682]
[0683]
[0684] Biological activity
[0685] Example A
[0686] Phospho-ERK1 / 2 assay
[0687] Functional assays were performed using Alphascreen Surefire phospho-ERK1 / 2 assays (Crouch & Osmond, Comb. Chem. High Throughput Screen, 2008). ERK1 / 2 phosphorylation is a downstream result of activation of both Gq / 11 and Gi / o protein-coupled receptors, making it highly suitable for evaluating M1, M3 receptors (Gq / 11 coupling) and M2, M4 receptors (Gi / o coupling), rather than using different assay formats for different receptor subtypes. CHO cells stably expressing human muscarinic M1, M2, M3 or M4 receptors were plated (25K / well) into MEM-α+10% dialyzed FBS on 96-well tissue culture plates. After adhesion, cells were serum starved overnight. Agonist stimulation was performed by adding 5 μL of agonist to cells for 5 min (37° C.). The culture medium was removed and 50 μL of lysis buffer was added. After 15 min, 4 μL of sample was transferred to a 384-well plate and 7 μL of detection mix was added. The plate was incubated in the dark with gentle agitation for 2 h and then read on a PHERAstar plate reader. pEC was calculated from the data obtained for each receptor subtype. 50 and E max The values are given in Table 4 below.
[0688] For the vast majority of embodiments, there are at least two diastereomers, and unless otherwise stated, these diastereomers have been separated using the techniques of reversed-phase HPLC, chiral HPLC or chiral SFC. The isomer distribution (isomer 1, isomer 2, etc.) is based on the retention time of the compound using the separation technique performed in the final purification step. Implicitly, this can be a reversed-phase HPLC retention time, a chiral HPLC retention time or a chiral SFC retention time, and the retention time will vary due to the compound.
[0689] Analytical data for the active isomers are reported in Table 3. Data for several weakly active compounds are included in Table 4 to highlight the absolute stereochemical preference.
[0690]
[0691]
[0692]
[0693] Equivalent solutions
[0694] The foregoing examples are presented for the purpose of illustrating the present invention, and should not be construed as imposing any limitation on the scope of the present invention. It will be readily apparent that many modifications and changes may be made to the specific embodiments of the present invention described above and illustrated in the examples, without departing from the principle as basis of the present invention. All such modifications and changes are intended to be included by the application.
Claims
1. A compound of formula (1): or a salt thereof, in: X 1 and X 2 are saturated hydrocarbon groups which together contain a total of five to nine carbon atoms and zero or one oxygen atom and are linked together such that the moieties: forming a monocyclic or bicyclic ring system; X 3 and X 4 are saturated hydrocarbon groups which together contain a total of three to six carbon atoms and are linked together such that the moieties: forming a monocyclic or bicyclic ring system; R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; or R 1 With R 2 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; R 2 is selected from hydrogen; fluorine; cyano; hydroxyl; amino; and C optionally substituted by one to six fluorine atoms 1-3 A hydrocarbon group, wherein one of the carbon atoms of the hydrocarbon group can be optionally replaced by a heteroatom selected from O, N and S and their oxidized forms; or R 2 With R 1 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; R 4 H, halogen, OH, CN, C 1-6 Alkyl group or C 3-6 A cycloalkyl group, wherein the alkyl group and the cycloalkyl group are optionally substituted by one or more fluorine atoms, and wherein any one atom of the alkyl group or the cycloalkyl group can be optionally replaced by an O heteroatom; R 5 Selected from hydrogen; COCH 3 ; non-aromatic C optionally substituted by one or more fluorine atoms 1-10 A hydrocarbon group wherein the C 1-10 Any atom of the hydrocarbon group can be optionally replaced by a heteroatom selected from O, N and S; the group -(CH 2 ) n - aryl, wherein n is 0-3; or R 5 Can be used with R 6 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms; R 6 is selected from hydrogen; non-aromatic C optionally substituted by one or more fluorine atoms 1-10 A hydrocarbon group wherein the C 1-10 Any atom of the hydrocarbon group can be optionally replaced by a heteroatom selected from O, N and S; the group -(CH 2 ) n - aryl, wherein n is 0-3; or R 6 Can be used with R 5 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms; and R 7 is a non-aromatic C optionally substituted by one or more fluorine atoms 1-6 Hydrocarbon group.
2. The compound according to claim 1, which is a compound of formula 1a: or a salt thereof, in: X 1 and X 2 are saturated hydrocarbon groups which together contain a total of five to nine carbon atoms and zero or one oxygen atom and are linked together such that the moieties: forming a monocyclic or bicyclic ring system; X 3 and X 4 are saturated hydrocarbon groups which together contain a total of three to five carbon atoms and are linked together such that the moieties: forming a monocyclic or bicyclic ring system; R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; or R 1 With R 2 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; R 2 is selected from hydrogen; fluorine; cyano; hydroxyl; amino; and C optionally substituted by one to six fluorine atoms 1-3 A hydrocarbon group, wherein one of the carbon atoms of the hydrocarbon group can be optionally replaced by a heteroatom selected from O, N and S and their oxidized forms; or R 2 With R 1 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; R 4 Is H or C 1-3 Alkyl groups; R 5 Selected from hydrogen, COCH 3 , non-aromatic C optionally substituted by one or more fluorine atoms 1-6 A hydrocarbon group, or R 5 Can be used with R 6 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms; R 6 is selected from hydrogen, non-aromatic C optionally substituted by one or more fluorine atoms 1-6 A hydrocarbon group, or R 6 Can be used with R 5 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms; and R 7 is a non-aromatic C optionally substituted by one or more fluorine atoms 1-6 Hydrocarbon group.
3. The compound according to claim 1 or claim 2, wherein R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ;COOR 7 ; an optionally substituted 5- or 6-membered ring containing 0, 1 or 2 nitrogen heteroatoms; or R 1 With R 2 Connected to form an optionally substituted monocyclic or bicyclic ring.
4. The compound according to claim 1 or claim 2, wherein R 1 With R 2 Connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1 or 2 heteroatoms selected from O or N.
5. The compound according to claim 4, wherein R 1 With R 2 connected to form an optionally substituted monocyclic or bicyclic ring containing 0, 1 or 2 heteroatoms selected from O or N, wherein the optional substituents are selected from C 1 -C 6 Alkyl, C 1 -C 3 Alkoxy, halogen, cyano, oxo, hydroxy, amino or the group -(CH 2 ) n -aryl, wherein n is 0-3.
6. The compound according to claim 1 or claim 2, wherein R 1 Selected from NR 5 R 6 ;CONR 5 R 6 ; or COOR 7 .
7. The compound according to claim 1 or claim 2, wherein R 1 is an optionally substituted 5- or 6-membered ring containing 0, 1 or 2 nitrogen heteroatoms, wherein the optional substituents are selected from C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, CONR 5 R 6 , halogen, cyano, oxo, hydroxy, amino or an optionally substituted heterocycle containing 1 or 2 heteroatoms selected from O or N, wherein the optional substituent is C 1 -C 3 alkyl.
8. The compound according to claim 6 or claim 7, wherein R 2 It is H or cyano.
9. The compound according to claim 1 or claim 2, wherein R 1 Selected from NR 5 R 6 ,CONR 5 R 6 or COOR 7 , and R 5 Selected from COCH 3 , non-aromatic C 1-6 A hydrocarbon group, or R 5 Can be used with R 6 Joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
10. The compound according to claim 9, wherein R 5 Selected from COCH 3 , non-aromatic C 1-6 A hydrocarbon group, or R 5 Can be used with R 6 are joined together to form an optionally substituted monocyclic ring, wherein the optional substituents are selected from C 1 -C 3 Alkyl, C 1 -C 3 alkoxy, halogen, cyano, oxo, hydroxy or amino.
